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1. INTRODUCTION 
 
1.1.  INFLAMMATORY BOWEL DISEASE 
Inflammatory bowel disease (IBD) is a general term for a group of chronic 
inflammatory disorders of unknown etiology involving the gastrointestinal tract
1
. Crohn’s 
disease (CD) and Ulcerative Colitis (UC) are inflammatory bowel diseases that cause chronic 
inflammation and damage in the gastrointestinal (GI) tract. Inflammation impairs the ability 
of affected GI organs to function properly, leading to symptoms such as persistent diarrhea, 
abdominal pain, rectal bleeding, weight loss and fatigue
2
. These are clinically characterized 
by recurrent inflammatory involvement of intestinal segments with several manifestations 
often resulting in an unpredictable course
1
. 
 
1.1.1.  ULCERATIVE COLITIS (UC) 
UC was described in the year of 1800 by Samuel Wilks. UC is characterized by 
continuous colonic mucosal inflammation that extends proximally from the rectum. It is a 
chronic disease that typically presents in the second or third decade of life with bloody 
diarrhoea and abdominal cramps
3
. In contrast with that of Crohn’s disease, the inflammation 
of ulcerative colitis is limited to the colonic mucosa. The portion of the colon affected varies. 
Some patients have inflammation that is limited to the rectum (ulcerative proctitis), whereas 
others have more proximal disease. Pancolitis refers to ulcerative colitis that affects the entire 
colon
4
. The difference between normal colon and ulcerative colon was given in Figure 1
5
. 
 
 
Figure 1: Difference between Normal Colon and Colon with UC 
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1.1.2.  ETIOLOGY 
The etiology is unknown. Risk factors include a history of recent infection with 
Salmonella or Campylobactor
4
. It is associated with an 8-10 times higher risk of developing 
ulcerative colitis in the following year
6
. UC has been hypothesized that it is an autoimmune 
disease in which the intestinal immune system attacks healthy intestinal cells and 
tissues.  Susceptibility to this abnormal behavior of the intestinal immune system may be 
genetically inherited.  People who have a first-degree relative (i.e. brother, sister, child, 
parent) with ulcerative colitis are more likely to develop the disease.  In recent years 
approximately 30 genes that might increase susceptibility to the disease have been 
identified.  Environmental factors may also play a role.  Factors such as stress and eating 
certain foods do not cause ulcerative colitis but may worsen the symptoms
7
. 
 
1.1.3.  EPIDEMIOLOGY 
UC is more prevalent than Crohn’s disease. North America and northern Europe have 
the highest incidence and prevalence rates of UC, with incidence varying from 9 to 20 cases 
per 1 lakh person-years and prevalence rates from 156 to 291 cases per 1 lakh people 
(Table:1). Rates are lowest in the southern hemisphere and eastern countries. Incidence has 
increased in countries that have adopted an industrialized lifestyle, which suggests that 
environmental factors might be crucial in the triggering of disease onset
8
. UC affects 
approximately 2.5 lakhs to 5 lakhs persons in the United States, with an annual incidence of 
2-7 per 1 lakh persons. The overall incidence of the disease has remained constant over the 
past 5 decades
9
. UC has a bimodal pattern of incidence, with the main onset peak between 
ages 15 and 30 years, 12 and a second smaller peak between ages 50 and 70 years. Studies 
have noted either no preference regarding sex, 13 or a slight predilection for men
8
. The 
disease affects men and women at similar rates
9
. 
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Table No.1: Incidence and Prevalence rates of UC from Selected Countries 
Authors Name Country Study period Incidence Prevalence 
Herrinton LJ et al., USA (California) 1996–2002 12 155·8 
Loftus CG et al., USA (Olmsted                              
County, MN) 
1990–2000 8·8 214 
Kappelman MD et al., US (33 states) 2003–2004 - 238 
Bernstein CN, et al., Canada 1998–2000 9·9-19·5 162–24 
Manninen P et al., Finland 1986–2000 19·6 291 
Vind I et al., Denmark 2003–2005 13·4 - 
Bjornsson S et al., Iceland 1990–1994 16·5 - 
Stewenius J et al., Sweden 1958–1982 9·4 - 
Rubin GP et al., England - 13·9 243·4 
 
However, 80% of the patients present with disease extending from the rectum to the 
splenic flexure and only 20% have pancolitis. 
 
1.1.4.  SYMPTOMS 
UC may be insidious, with gradual onset of symptoms or the first attack may be acute 
and fulminate. More mild symptoms include a progressive loosening of the stool, abdominal 
cramping and diarrhoea. As the disease progresses from mild to more severe, the patient may 
also experience weight loss, fatigue, loss of appetite that may result in nutrient deficiencies, 
mucus in the stool, severe rectal bleeding, fever and anaemia
10
. In some cases, extra intestinal 
manifestations may be present as well. Extra intestinal symptoms can be an initial 
manifestation or can occur later in the course of the disease
1
. Initial symptoms of UC are 
given in Table No.2
1,10
. Extra intestinal manifestations of UC are given in Table No.3
9
. 
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Table No.2: Symptoms and Effects of UC 
Symptoms Effects Percentage 
Area of intestinal tract 
affected 
Any part of inner most lining of colon, 
continuous with no "patches" of normal tissue 
 
- 
Diarrhoea Typically  four episodes per day 96.4% 
Abdominal pain/cramping Mild tenderness, lower abdominal cramping 81.3% 
Blood in stool Present; amount depends on disease severity 89.3% 
Fatigue Result of excessive blood loss and anaemia - 
Physical examination Rectal exam may show peri-anal irritation, 
fissures, haemorrhoids, fistulas and abscesses 
40.2% 
Weight loss/anorexia Weight loss in more severe cases 38.4% 
Loss of appetite Often decreased during periods of disease 
exacerbation 
15.2% 
Fever - 20.5% 
Nausea - 6.3% 
Vomiting - 4.5% 
Skin changes - 20.5% 
Risk of colon cancer Increased - 
 
Table No.3: Extra intestinal Manifestations of UC 
Extra intestinal manifestations Frequency (%) 
Osteoporosis  15.0 
Oral ulcerations  10.0 
Arthritis  5.0 to 10.0 
Primary sclerosing cholangitis  3.0 
Uveitis  0.5 to 3.0 
Pyoderma gangrenosum  0.5 to 2.0 
Deep venous thrombosis  0.3 
Pulmonary embolism  0.2 
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1.1.5.  DISEASE SEVERITY AND LOCATION 
The severity of UC can be characterized as mild, moderate, severe or fulminant mild 
disease consists of fewer than 4 stools per day (with or without blood) without systemic signs 
of toxic effects and normal inflammatory markers. Moderate disease is defined as 4 or more 
bloody stools per day with minimal signs of toxic effects. Severe disease is classified as more 
than 6 bloody stools per day with evidence of systemic toxic effects including fevers, 
tachycardia, anaemia or elevated inflammatory markers. Fulminant disease is characterized 
by having more than 10 bloody bowel movements and clinical signs of toxic effects including 
abdominal distension, blood transfusion requirements and colonic dilation on imaging
3
.  The 
severity of UC is given in Figure 2
11
. 
 
 
 
 
 
Figure 2: Severity of UC 
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1.1.6.  TYPES OF ULCERATIVE COLITIS 
UC can be categorized on the basis of the extent of the disease. The type of UC can be 
given in Figure 3
12
. 
 
Figure 3: Types of UC 
 
Types of UC
13
: 
i. Proctitis  : Limited to rectum. 
ii. Proctosigmoiditis : Involves rectum and sigmoid colon (Lower segment). 
iii. Distal colitis   : Extends from rectum and entire left colon. 
iv. Extensive colitis : Involves more than half the colon or the entire colon. 
v. Pancolitis  : Affects the entire large intestine.  
 
1.1.7.  PATHOPHYSIOLOGY 
Disruption of tight junctions and the mucus film covering the epithelial layer causes 
increased permeability of the intestinal epithelium, resulting in increased uptake of luminal 
antigens. Macrophages and dendritic cells (innate immune cells) on recognition of non-
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pathogenic bacteria (commensal microbiota) through molecular pattern recognition receptors 
(TLR) change their functional status from tolerogenic to an activated phenotype.  
Activation of NF-kB pathways stimulates the transcription of pro inflammatory genes, 
resulting in increased production of pro-inflammatory cytokines (TNF-α, interleukins 12, 23, 
6, and 1β). After processing of antigens, macrophages and dendritic cells present them to 
naive CD4 T-cells, promoting differentiation into Th2 effector cells, characterised by 
production of interleukin 4. Natural-killer T cells are the main source of interleukin 13, which 
has been associated with disruption of the epithelial cell barrier.  
Circulating T cells bearing integrin-α4β7 bind to colonic endothelial cells of the 
microvasculature through the mucosal vascular address in-cell adhesion molecule 1, whose 
expression is enhanced in the inflamed intestine, leading to increased entry of gut-specific T 
cells into the lamina propria. Up-regulation of inflammatory chemokines such CXCL1, 
CXCL3 and CXCL8 leads to recruitment of circulating leucocytes which perpetuates the 
cycle of inflammation. The pathophysiology of UC is given in Figure 4
8
. 
 
Figure 4: Pathophysiology of UC 
Note: TLR– Toll-like receptor, HLA– human leucocyte antigen, IL – interleukin, TN– 
tumour necrosis factor, NF-κB–nuclear factor-κB, Th– T-helper, NKT– natural killer T-cell, 
CXCL– chemokine,  Treg– regulatory T cell, MAdCAM-1– mucosal address in-cell adhesion 
molecule 1. 
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1.1.8.  COMMON TESTS TO DIAGNOSE AND MAINTAIN UC13 
1. Diagnostic testing  
 Fecal sample (Presence of bacteria, Parasites)  
 Blood sample (Infection, Anaemia, Inflammatory markers)  
 Biopsy of Intestinal lining  
 Liver and kidney function tests  
2. Endoscopy  
 Gold standard for UC diagnosis 
 Flexible scope inserted into rectum  
 Sigmoidscope examines lower third of colon 
 Colonoscopy examines entire colon  
3. Visual examination  
 Radiograph (Image shows constrictions)  
 Barium enema (Radio-opaque) 
 CT scan provides more detail than x-rays 
 
1.1.9.  TREATMENTS FOR UC 
 Treatment of UC was based on the types and severities of the disease
14
. 
 
Figure 5: Treatment for UC 
 
Several categories of drugs may be effective in the treating UC. The type of drugs 
taken will be depending on the severity of disease condition. Classifications of drugs are 
given in Table No.4. 
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Table No.4: Classification of UC Drugs
2-4, 15-21 
Name Dose Brand Dosage form 
ANTI-INFLAMMATORY DRUGS 
Sulfasalazine 500 mg Azulfidine Tablet 
Mesalamine 0.375gm Aspiro Extended release capsules 
Mesalamine 400 mg Asacol Delayed release tablet 
Mesalamine 1.2 gm Lialda Delayed release tablet 
Mesalamine 4 gm per 60 ml Rowasa Enema 
Mesalamine 1000 mg Canasa Suppositories 
Mesalamine 250 and 500 mg Pentasa Controlled release capsules 
Mesalamine 1 gm in 100ml Pentasa Enema 
Mesalamine  - 
Pentasa   Enema 
1% 
Enema 
Balsalazide 750 mg Colazal Capsules 
Olsalazine 250 mg Dipentum Capsules 
CORTICOSTEROIDS 
Prednisolone 5 mg Reyos Tablet 
Prednisolone 20 mg/100 ml Predsol Retension enema 
Prednisolone 20 mg/100 ml Predenema Enema 
Budesonide 3 mg Entocort Controlled release Capsules 
Budesonide 0.02 mg/ ml Entocort Enema 
Budesonide 0.2 mg/ ml Entocort Apulein Enema 
IMMUNE SYSTEM SUPPRESORS 
Azathioprine 75 mg, 100 mg Azasan Scored tablets 
Azathioprine 50 mg Imuran Scored tablets 
Mercaptopurine 50 mg Purinethol Scored tablets 
Mercaptopurine 50 mg Purixam Oral suspension 
CALCINEURIN INHIBITORS 
Cyclosporine 25, 50, 100 mg Gengraf Capsules 
Cyclosporine  - Neoral Capsules and Oral solutions 
Cyclosporine  - Sandimmune 
Soft gelatin capsules, Oral solutions 
and Injection 
ANTI-TNF AGENTS 
Infliximab - Remicade Intravenous powder for Injection 
Adalimumab - Humira Subcutaneous injection 
Golimumab - Simponi Self Injection 
Vedolizumab - Entyvio. Intravenous infusion 
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1.1.10.  OTHER MEDICATIONS3 
1. Antibiotics 
2. Anti-diarrheal agents 
3. Pain relievers 
4. Iron supplements 
 
 
1.1.11. SURGERY 
1, 3 
In UC, three situations are absolute indications for surgery: Exsanguinating 
haemorrhage, Frank perforation and Documented or strongly suspected carcinoma i.e. high 
grade dysplasia or low grade dysplasia in a mass lesion. Massive haemorrhage in UC is due 
to diffuse mucosal ulceration. If the hemorrhage is exsanguinating or even persisting despite 
maximal medical therapy, it is an indication for surgical treatment. Perforation (occurring in 
only 2-3 % of hospitalized UC patients at tertiary referral centers), is the most lethal 
complication of toxic megacolon. When colon cancer is identified, the need for surgery is 
obvious; similarly, the colonoscopic biopsy diagnosis of high grade dysplasia is often 
indicative of a concomitant or future cancer and is an indication for colectomy. Severe UC 
unresponsive to an intensive medical regimen or toxic megacolon are others indications for 
surgery. 
 
 
1.1.11.  ROUTE OF ADMINISTRATION 
The UC drugs are given in following route of administration. 
 Oral route 
 Parentral route 
 Rectal route 
 
 
 
 
 
 
CHAPTER 1                                                                                                 INTRODUCTION 
DEPARTMENT OF PHARMACEUTICS, S.B.C.P, SIVAKASI.  Page 11 
1.2.  RECTAL DOSAGE FORMS22 
Rectal administration is not often the first route of choice; but it becomes a good 
alternative when the oral route is inadvisable. Relatively low cost and lack of technical 
difficulties make rectal drug administration attractive when compared to parenteral therapy. 
The downside of rectal administration includes the aesthetics and stigma of violating the 
patient’s dignity.  This along with potential rectal irritation due to frequent administration and 
difficulty in titrate a correct dose due to limited strengths of commercial rectal dosage forms 
pose some challenges.  
Psychologically, rectal dosage forms can provide a considerable placebo effect in the 
treatment of ano-rectal disorders. The user feels that something is really being done at the 
involved site and this can produce a positive attitude towards this mode of treatment of the 
disease or disorder. This may promote hope and the possibility of avoiding the 
embarrassment of telling the family and friends of what is happening in the private area. 
Previously, the rectal pathway was reserved for the administration of locally active 
products such as those in the treatment of haemorrhoids, worms and constipation.  In the 
treatment of haemorrhoids and anal fissures, a suggestion was made at one time that a 
suppository should be “hour glass” or “collar button” shaped so that the suppository would 
stay in the anal canal. 
Now, it is well accepted that many active ingredients can be administered rectally and 
achieve therapeutic blood levels from any of several different dosage forms. Some 
medications are best administered by this route while others can be if needed. 
 
1.2.1. ANATOMICAL AND PHYSIOLOGICAL CONSIDERATIONS
22
 
The rectum consists of the last few inches of the large intestine, terminating at the anus. 
The wall of the GI tract consists of several layers including the mucosa, submucosa, tunica 
muscularis and the visceral peritoneum. The mucous membrane of the rectum, where rectal 
dosage forms are generally administered, is made up of a layer of cylindrical epithelial cells 
differentiated from those of the intestine by the absence of villi. 
The rectum contains three types of haemorrhoidal veins, namely the superior 
hemorrhoidal vein, middle haemorrhoidal vein and the inferior haemorrhoidal vein. These 
veins are act by transporting the active principle absorbed in the rectum to the blood system 
either directly by means of iliac veins and the vena cava (inferior and middle hemorrhoidal 
veins) or indirectly by means of the portal vein and the liver (superior hemorrhoidal vein). 
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The three hemorrhoidal veins are linked by an anastomosis network. Since it is not 
really possible to predict the position or exact location of the dosage form in the rectum, it is 
not really possible to predict exactly which way the active principle will be transported. It 
may be preferably by one pathway or another or a combination. However, it is generally 
accepted that at least 50% to 70% of the active ingredients administered rectally take the 
direct pathway thus bypassing the liver and avoiding the first-pass effect. There is also the 
possibility of absorption into the lymphatic vessels that should not be dismissed but may be 
minimal. 
 
1.2.2. ADVANTAGES OF RECTAL ADMINISTRATION
24, 25 
The advantages of rectal administration include the following 
1. First pass effect 
Avoiding at least partially the first pass effect which may result in higher 
blood levels for those drugs subject to extensive first pass metabolism upon oral 
administration.  
2. Drug stability 
Avoiding the breakdown of certain drugs that is susceptible to gastric 
degradation.  
3. Large dose drugs  
Ability to administer somewhat larger doses of drugs than using oral 
administration.  
4. Irritating drugs 
Ability to administer drugs which may have an irritating effect on the oral or 
GI mucosa when administered orally.  
5. Unpleasant tasting or smelling drugs  
Ability to administer unpleasant tasting or smelling drugs whose oral 
administration is limited.  
6. In children, the rectal route is especially useful. An ill child may refuse oral 
medication and may fear injections.  
7. Rectal administration can be especially useful in terminal care.  
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Rectal administration provides for a rapid and in many cases extensive absorption of 
the active ingredient. The rapidity, intensity and duration of action are three parameters 
which must be considered during formulation for rectal administration and in many cases can 
be altered to meet the needs of the individual patient. 
 
1.2.3. DISADVANTAGES
24, 25 
       The disadvantages of rectal administration include the following, 
1. Erratic absorption – drug absorption from a suppository is often incomplete and 
erratic. 
2. Absorption from solutions used as an enema may be more reliable. 
3. Not well accepted, may be some discomfort. 
4. Self medication is not possible. 
 
1.3. ENEMA 
An enema is a solution or fluid suspension for rectal administration. There are two 
types:  evacuant enemas and retention enemas. The volume given varies according to the type 
of enema. Retention enemas do not normally exceed 100 ml in volume; evacuant enemas 
may be as much as 2:1. Large volume enemas should be warmed to body temperature before 
administration
26
. Enemas are dosage forms designed to be administered rectally for clearing 
out the bowel or for administration of drugs or food. An enema is a method of administration 
and may involve solutions, suspensions, emulsions, foams and gels
24
. The medical name for 
an enema is “enteroclysis.” However, enema is the more commonly used term. In the 17th 
century, clyster was used to describe the enema process. The process was performed using a 
“clyster syringe.” The syringe consisted of a nozzle that entered the rectum and a plunger. 
During this time, an apothecary would administer the procedure. Women were often 
embarrassed if a male administered the enema. Most women were modest and did not enjoy 
their private parts being exposed. Now, individuals may administer the enema themselves 
without any assistance. In the 19
th
 century, clyster syringes were replaced with enema bags 
and rectum nozzles
27
. 
 
1.3.1. RETENTION ENEMAS
24 
A number of solutions, suspensions and emulsions are administered rectally for the 
local effects of the medication (e.g. hydrocortisone) or for systemic absorption (e.g. 
aminophylline). In the case of aminophylline, the rectal route of administration minimizes the 
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undesirable gastrointestinal reactions associated with oral therapy. Clinically effective blood 
levels of the agents are usually obtained within 30 minutes following rectal instillation. 
Corticosteroids can be administered as retention enemas as adjunctive treatment of some 
patients with UC. 
 
1.3.2. EVACUATION ENEMAS
24 
Rectal enemas are used to cleanse the bowel. Commercially, many enemas are 
available in disposable plastic squeeze bottles containing a premeasured amount of enema 
solution. The agents present are solutions of sodium phosphate, sodium biphosphate, 
glycerin, docusate potassium and light mineral oil. It may be prepared as solutions, 
suspensions, emulsions, powder and tablet for solution and suspensions. 
 
1.3.3. SOLUTIONS
22 
 Considerations in preparing solutions include solubility, solvent selection, pH, 
osmolality and stability of the drug. If the pH is too low or too high, it may be irritating to the 
mucosa. If the solution is hyperosmolar, it may pull fluids from the local area and initiate a 
defecation reflex. 
 
1.3.4. SUSPENSIONS
22
  
Suspensions are preparations containing finely divided drug particles distributed 
somewhat uniformly throughout a vehicle in which the drug exhibits a minimum degree of 
solubility. In most good pharmaceutical suspensions, the particle diameter is between 1 and 
50 microns. The pharmacist may have to use a solid dosage form (e.g. tablet and capsule) of 
the drug and extemporaneously compound a liquid preparation or it can be made from the 
bulk powder. Typically, when formulating an extemporaneous suspension, the contents of a 
capsule, crushed tablets or bulk powder is placed in a mortar. The selected vehicle is then 
slowly added and mixed with the powder to create a paste and then diluted to the desired 
volume. To minimize stability problems of the extemporaneously prepared product, it should 
be placed in air-tight, light-resistant containers by the pharmacist and subsequently stored in 
the refrigerator by the patient. Because it is a suspension, the patient should be instructed to 
shake it well prior to use and on a daily basis watch for any color change or consistency 
change that might indicate a stability problem with the formulation. The following examples 
of rectal suspensions have frequently been compounded by pharmacists when not 
commercially available.  Barium Sulfate for Suspension, U.S.P has been employed orally or 
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rectally for the diagnostic visualization of the gastrointestinal tract. Mesalamine (i.e. 5-
aminosalicylic acid) suspension was introduced onto the market in 1988 as Rowasa® 
(Solvay) for treatment of Crohn’s disease, distal UC, proctosigmoiditis and proctitis. 
 
1.3.5. EMULSIONS
22 
An emulsion is a dispersion in which the dispersed phase is composed of small 
globules of a liquid distributed throughout a vehicle in which it is immiscible. 
Pharmaceutically, the process of emulsification enables the pharmacist to prepare relatively 
stable and homogeneous mixtures of two immiscible liquids. It permits the administration of 
a liquid drug in the form of minute globules rather than in bulk. The initial step in preparation 
of an emulsion is the selection of the emulsifier. Among the emulsifiers and stabilizers for 
pharmaceutical systems are some carbohydrate materials (acacia, tragacanth, agar, chondrus 
and pectin), protein substances (gelatin, egg yolk and casein), high molecular weight alcohols 
(stearyl alcohol, cetyl alcohol and glyceryl monostearate), wetting agents (which may be 
anionic, cationic or nonionic) and finely divided solids  (colloidal clays including bentonite, 
magnesium hydroxide and aluminum hydroxide). Emulsions may be prepared by several 
methods, depending upon the nature of the emulsion components and the equipment available 
for use. On a small scale, as in the laboratory or pharmacy, emulsions may be prepared using 
a dry wedgewood or porcelain mortar and pestle, a mechanical blender or mixer such as a 
waring blender or a milk-shake mixer, a hand homogenizer, a bench-type homogenizer or 
sometimes a simple prescription bottle. On a large scale, large volume mixing tanks may be 
used to form the emulsion through the action of a high speed impeller. As desired, the 
product may be rendered finer by passage through a colloid mill, in which the particles are 
sheared between the small gap separating a high speed rotor and the stator or by passage 
through a large homogenizer, in which the liquid is forced under great pressure through a 
small valve opening.  
 
1.3.6. POWDERS / TABLETS FOR RECTAL SOLUTIONS AND SUSPENSIONS
23 
  Powders / tablets intended for the preparation of rectal solutions or suspensions are 
single-dose preparations that are dissolved or dispersed in water or other suitable solvents at 
the time of administration. They may contain excipients to facilitate dissolution or dispersion 
or to prevent aggregation of the particles. After dissolution or dispersion the preparation 
complies with the requirements for rectal solutions or rectal suspensions as appropriate. 
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1.4. TABLETS 
Tablet is defined as a compressed solid dosage form containing medicaments with or 
without excipients
28
. According to the I.P Pharmaceutical tablets are solid flat or biconvex 
dishes unit dosage form prepared by compressing a drugs or a mixture of drugs with or 
without diluents. They vary in shape and differ greatly in size and weight, depending on 
amount of medicinal substances and the intended mode of administration. It is the most 
popular dosage form and 70% of the total medicines are dispensed in the form of tablet. All 
medicaments are available in the tablet form except where it is difficult to formulate or 
administer
29
. 
 
1.4.1. DISPERSIBLE TABLETS30-32 
 Dispersible tablets are uncoated or film‐coated tablets that can be dispersed in liquid 
before administration giving a homogenous dispersion. Dispersible tablets usually 
disintegrate within three minutes when put in water. 
 
1.4.1.1. ADVANTAGES OF DISPERSIBLE TABLETS
33 
1. More convenient for active pharmaceutical ingredients with insufficient 
stability in water.  
2. More easily transportable and they generate less handling and transportation 
costs for the same amount of active ingredient (less volume and less weight). 
3. Easier to produce and the production costs are less, which makes them more 
affordable than standard liquid formulations. 
Dispersible tablets have less physical resistance than regular tablets; they are more 
sensitive to moisture and may degrade at higher humidity conditions. Each tablet must be 
protected from the ambient humidity. The dispersible tablets should not be divided or 
chewed. Dispersible tablets must be used immediately after removal from the blister 
packaging. Their stability outside of the blister cannot be guaranteed. 
 
1.4.1.2. DISADVANTAGES OF DISPERSIBLE TABLETS
32 
1. It is hygroscopic in nature so must be keep in dry place. 
2. It is also shows the fragile, effervescence granules property. 
3. It requires special packaging for properly stabilization and safety of stable 
product. 
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1.4.1.2.MECHANISMS OF DISINTEGRATION
32
 
Disintegrating tablets involve the following mechanisms to achieve the desired fast 
dissolving.  
1. Water must quickly enter into the tablet matrix to cause rapid disintegration and 
instantaneous dissolution of the tablet. 
2. Incorporation of an appropriate disintegrating agent or highly water soluble excipients 
in the tablet formulation. 
3. There are some under mentioned mechanisms by which the tablet is broken down into 
the smaller particles and then subsequently result a solution or suspension of the drug.  
The mechanisms are
34
 - 
 Swelling 
 Porosity and Capillary Action (Wicking) 
 Deformation 
 Due to disintegrating particle/particle repulsive forces 
 
1.4.1.4.STAGES OF DISINTEGRATION
35 
The different stages of disintegration of dispersible tablets were shown in Figure 6. 
 
 
 
Figure 6: Disintegration Stages of Dispersible Tablets 
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1.4.1.5.FORMULATION OF DISPERSIBLE TABLETS 
Selection of Excipients 
Mainly seen excipients in dispersible tablets are as follows at least one disintegrant, a 
diluent, a lubricant and optionally a swelling agent, etc. 
Ideal bulk excipients for disintegrating dosage forms should have the following properties  
1. Disperses and dissolves within a few seconds without leaving any residue. 
2. Enables sufficient drug loading and remains relatively unaffected by changes in 
humidity or temperature. 
Excipients used for the formulation of dispersible tablet were given in Table No.5. 
 
 
 
 
Table No.5: Details of Excipients used for the Formulation of Dispersible Tablets 
Excipients Function Examples 
Superdisintegrant Increases the rate of disintegration 
and hence the dissolution. The 
presence of other formulation 
ingredients such as water-soluble 
excipients and effervescent agents 
further hastens the process of 
disintegration. For the success of 
fast dissolving tablet, the tablet 
having quick dissolving property, 
which is achieved by using the 
superdisintegrant. 
Crospovidone, microcrystalline 
cellulose, sodium starch glycolate, 
sodium carboxy methyl cellulose, 
pregelatinzed starch, carboxy methyl 
cellulose and modified corn starch. 
Sodium starch glycolate has good 
flow ability than croscarmellose 
sodium. Crospovidone is fibrous 
nature and highly compactable. 
Surface active 
Agents 
Reduces interfacial tension and 
thus enhances solubilisation of 
FDT. 
Sodium doecyl sulfate, sodium lauryl 
sulfate, polyoxyethylene sorbitan, 
fatty acid esters (Tweens), sorbitan 
fatty acid esters (Spans) and 
polyoxyethylene stearates.  
Binders Maintains integrity of dosage form 
prior to administration. 
Polyvinylpyrrolidone (PVP), 
polyvinylalcohol (PVA) and hydroxy 
propyl methylcellulose (HPMC). 
Lubricants Lubricants help to reduce friction 
and wear by introducing a 
lubricating film between 
mechanical moving parts of tablet 
punching machine. 
Stearic acid, magnesium stearates, 
zinc state, calcium state, talc, 
polyethylene glycol, liquid paraffin, 
magnesium lauryl sulphate and 
colloidal silicon dioxide. 
Fillers Enhances bulk of dosage Form. Directly compressible spray dried 
mannitol, sorbitol, xylitol, calcium 
carbonate, magnesium carbonate, 
calcium phosphate, calcium sulfate, 
pregelatinzed starch, magnesium 
trisilicate and aluminium hydroxide. 
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1.4.1.6.PREPARATION OF DISPERSIBLE TABLETS
36, 37 
Tablet Processing 
Pharmaceutical products are processed all over the world using the direct 
compressing, wet granulation or dry granulation methods. Method chosen depends on the 
ingredient’s individual characteristics like flow property, compressibility etc. Right choice of 
method requires thorough investigation of each proposed ingredient in the formula for 
comprehensive approach for interactions and stability. 
The process of tablet manufacturing was given in Figure 7. 
 
 
Figure 7: Process of Tablet Manufacturing 
 
Direct Compression 
The tablets are made by directly compressing the powdered materials without 
modifying the physical nature of the materials itself. Direct compression is generally done for 
the crystalline materials having good physical properties such as flow property, 
compressibility, etc. Main advantages of direct compression are time saving, safety of 
operations and low cost. 
 
Wet Granulation 
This is the most widely used method of tablet preparation. In this method the powders 
are bound by suitable binder by adhesion”. The binder is added by diluting with suitable 
solvent prior to addition to the blended powders to form wet granules which is dried suitably 
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to expel the solvent forming dried granules. The surface tension forces and capillary pressure 
are primarily responsible for initial granules formation. The main advantage being it meets all 
the requirements for tablet formation though it is multi stage and time consuming. 
 
Dry Granulation 
The dry granulation process is used to form granules without using a liquid solution. 
This type of process is recommended for products, which are sensitive to moisture and heat. 
Forming granules without moisture requires compacting and densifying the powders. Dry 
granulation can be done on a tablet press using slugging tooling. 
 
Slugging Method 
 Slugging method is a double compression method. Initially the powders are 
compressed in large size of punch. The compressed tablets were crushed into granules using 
mortar and pestle. Those granules were passed through initially by 16 # mesh then by 20 # 
mesh and finally passed through 30 # sieve mesh to get uniformed granules. Finally the 
granules are compressed to get uniform weight of tablet. 
 
1.4.2. EVALUATION PARAMETERS38, 39 
Tablets when formulated may undergo physical and chemical changes, which may 
alter their bioavailability. Therefore, the tablets are to be evaluated before dispensing to 
ensure their stability and bioavailability throughout their shelf life. Evaluation of tablets can 
be carried out by the following test. 
Pre-compression Parameters 
 Loss on drying 
 Bulk density 
 Tapped density 
 Carr’s index 
 Hausner’s ratio 
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Evaluation of Dispersible Tablets 
 
 Tablet appearance 
 Organoleptic parameters 
 Identification markings on the tablets 
 Hardness  
 Thickness  
 Weight variation test 
 Friability  
 In-vitro dispersion time 
 Wetting time 
 Water absorption ratio 
 Uniformity of disintegration 
 Disintegration test 
 Drug content estimation 
 In-vitro dissolution test 
 
1.5. VEHICLE40 
Vehicle solution is a homogenous mixture composed of two or more substances. In 
such a mixture, a solute is a substance dissolved in another substance, known as solvent. The 
mixing process of a solution happens at a scale where the effects of chemical polarity are 
involved, resulting in interactions that are specific to salvation. The solution assumes the 
characteristics of the solvent when the solvent is the larger function of the mixture, as is 
commonly the case. The concentration of a solute in a solution is the mass of that solute 
expressed as a percentage of the mass of the whole solution. 
 
 
SOLUTE + SOLVENT                       SOLUTION 
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1.5.1. CHARACTERISTICS OF VEHICLE 
1. A solution is a homogenous mixture of two or more substances. 
2. The particles of solute in a solution cannot be seen by the naked eye. 
3. A solution does not allow beams of light to scatter. 
4. A solution is should be stable. 
5. The solute from a solution cannot be separated by filtration (or mechanically). 
6. It is composed of only one phase. 
 
1.5.2. INGREDIENTS IN THE VEHICLE  
 Isotonic agent 
 Co-solvents 
 Preservatives 
 Suspending agents 
 Purified water 
Isotonic agent
41 
 Isotonic agent is a substance to maintain tonicity of the fluid to the body fluid. 
Sodium chloride is the example for isotonic agent 
Co-solvent
42 
A second solvent added in small quantities to enhance the solvent power of the 
primary solvent.  
Examples: Alcohol, poly ethylene glycol, propylene glycol and glycerin or glycerol 
etc. 
Preservatives
43 
Preservatives are substances which are added to various pharmaceutical dosage forms 
and cosmetic preparations to prevent or inhibit microbial growth. An ideal preservative 
would be effective at low concentrations against all possible microorganisms be nontoxic and 
compatible with other constituent of the preparation and be stable for the shelf-life of the 
preparation. 
Preservatives can be classified as 
i) Acids: e.g. Benzoic acid, sorbic acids, boric acids,  
ii) Esters: e.g. Methylparaben, ethylparaben, propylparaben, butylparaben, 
sodium benzoate, sodium propionate, potassium sorbate. 
iii) Alcohols: e.g. Chlorobutanol, benzyl alcohol, phenyl ethyl alcohol. 
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iv) Phenols: e.g. Phenol, chlorocresol, O-phenyl phenol. 
v) Mercurial compounds: e.g. Thiomersal, nitromersol, phenylmercuric nitrate, 
phenylmercuric acetate. 
vi) Quaternary ammonium compounds: e.g. Benzalkonium chloride, cetyl 
pyridinium chloride. 
Suspending agents
44 
 Suspending agents are help to active pharmaceutical ingredients stay suspended in the 
formulation and prevent caking at the bottom of the container. One of the properties of a 
well-formulated suspension is that it can be easily resuspended by the use of moderate 
agitation or shaking. 
Examples: Alginates, methyl cellulose, hydroxy methyl cellulose, carboxy ethyl 
cellulose, sodium carboxy methyl cellulose, microcrystalline cellulose, acacia, tragacanth, 
xanthan gum, bentonite, carbomer, carageenan, powdered cellulose and gelatin. 
 
1.6. SUSPENSIONS22 
Suspensions (Rectal) are liquid preparations intended for rectal application to obtain a 
local or systemic effect or they may be intended for diagnostic purposes. 
Suspensions are preparations containing finely divided drug particles distributed 
somewhat uniformly throughout a vehicle in which the drug exhibits a minimum degree of 
solubility. In most good pharmaceutical suspensions, the particle diameter is between 1 and 
50 microns. The pharmacist may have to use a solid dosage form (e.g. tablet and capsule) of 
the drug and extemporaneously compound a liquid preparation or it can be made from the 
bulk powder.  
Typically, when formulating an extemporaneous suspension, the contents of a 
capsule, crushed tablets or bulk powder is placed in a mortar. The selected vehicle is then 
slowly added and mixed with the powder to create a paste and then diluted to the desired 
volume. To minimize stability problems of the extemporaneously prepared product, it should 
be placed in air-tight light-resistant containers by the pharmacist and subsequently stored in 
the refrigerator by the patient.  
Because it is a suspension, the patient should be instructed to shake it well prior to use 
and on a daily basis watch for any color change or consistency change that might indicate a 
stability problem with the formulation. The following examples of rectal suspensions have 
frequently been compounded by pharmacists when not commercially available.  Barium 
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Sulfate for suspension, U.S.P has been employed orally or rectally for the diagnostic 
visualization of the gastrointestinal tract.  
Mesalamine (i.e. 5-aminosalicylic acid) suspension was introduced onto the market in 
1988 as Rowasa® (Solvay) for treatment of Crohn’s disease, distal ulcerative colitis, 
proctosigmoiditis and proctitis. Hydrocortizone rectal suspension was introduced from Ani 
pharmaceuticals, Baudette
45
. Mesalazine rectal suspension was introduced as Pentasa enema 
by Ferring Pharmaceuticals
46
. 
 
1.6.1. PREPARATION OF RECTAL SUSPENSION 
 One dispersible tablet was placed into a clear bottle containing vehicle solution for 
rectal suspension. Shake well until the tablet was completely dispersed. 
 
TABLET + VEHICLE SOLUTION                             SUSPENSION 
 
1.6.2. EVALUATION OF SUSPENSIONS 
 Sedimentation volume 
 Degree of flocculation 
 Re-dispersibility 
 pH 
 viscosity 
 Microbiology test 
 In-vitro drug release test 
 Accelerated stability studies 
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2. AIM AND PLAN OF WORK 
2.1. AIM AND OBJECTIVE 
To formulate and evaluate Prednisolone retention enema as dispersible tablet with 
vehicle. 
Prednisolone is a type of medicine called corticosteroid. It decreases immune 
system’s response in various diseases to reduce symptoms such as pain, swelling and allergic 
type reactions. Prednisolone is 4 times more potent than hydrocortisone, also more selective 
glucocorticoid. It reduces inflammation by stopping cells from releasing chemicals that 
normally help to produce immune and allergic responses
47-49
. 
Riboflavin is an integral component of two enzymes FAD (flavin adenine 
dinucleotide) and FMN (flavin mononucleotide). FAD and FMN are involved in the activity 
of electron transport chain, an essential component of energy metabolism. Prednisolone 
decreases the inflammation by inhibiting the migration of polymorphonuclear leukocytes and 
reversal of increased capillary permeability. It suppresses the immune system by reducing the 
activity and protection of the lymphocytes and eosinopril. Riboflavin helps in this place to 
increase the energy metabolism in lymphocytes and eosinopril
50
. 
 
The objectives of this study are following 
 
1. To formulate dispersible tablet and vehicle as enema formulation. 
2. To select excipients and find any incompatibility between the drug and excipients. 
3. To formulate Prednisolone dispersible tablet and vehicle. 
4. To perform the precompression and tablets evaluation parameters. 
5. To select the best formulation of dispersible tablet. 
6. To prepare rectal suspension using best formulation of dispersible tablet. 
7. To perform in-vitro drug release study for rectal suspension. 
8. To conduct Microbiology studies for the rectal suspension. 
9. To perform stability studies for the selected formulation of dispersible tablet. 
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2.2. PLAN OF WORK 
 
The plan of this work can be outlined below, 
 To carry out the preformulation studies for API 
 Description 
 Solubility 
 Melting point 
 Particle size distribution 
 Loss on drying 
 Flow properties 
 Drug excipients compatibility studies 
 Physical observation 
 Formulation of Prednisolone dispersible tablets by direct compression, wet 
granulation method and slugging method. 
 Evaluation for precompression parameters 
 Angle of repose 
 Bulk density 
 Tapped density 
 Compressibility index 
 Hausner’s ratio 
 Moisture content 
 Evaluation of post compression parameters for compressed tablets 
 Hardness 
 Thickness 
 Weight variation 
 Friability 
 Disintegration test 
 Wetting time 
 Water absorption ratio 
 In-vitro dispersion time 
 Uniformity of dispersion 
 Drug content estimation 
 IR spectral analysis 
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 Formulation of vehicle solution for suspending Prednisolone dispersible tablet 
 Formulation of rectal suspension using selected formulation of dispersible tablet. 
 Evaluation of rectal suspension 
 Appearance 
 Colour 
 pH 
 Viscosity 
 In-vitro drug release study 
 Microbiological evaluation. 
 Accelerated stability studies. 
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3. LITERATURE REVIEW 
1. Enemacort Retention enema (2012)
51
 is a dispersible tablet and solution for rectal 
suspension (2 mg budesonide/100 ml). Enemacort consists of two components, dispersible 
tablet (yellow circular tablet containing 2.3 mg budesonide) and vehicle 115 ml clear 
colourless solution. Tablet contains riboflavin 5-sodium phosphate, microcrystalline 
cellulose, croscarmellose sodium, maize starch, colloidal silicon dioxide, lactose anhydrous, 
magnesium stearate and purified talc. Vehicle contains sodium chloride, methyl paraben, 
propyl paraben, carboxy methyl cellulose sodium, propylene glycol and purified water.  
2. Entocort (2014)
52
 is a tablet and solution for rectal suspension. Total quantity of 
budesonide in a dose of prepared rectal suspension (115 ml) is 2.3 mg. Entocort rectal 
suspensions consists of two parts; a dispersible tablet, containing micronized budesonide and 
an isotonic solution. The rectal suspension is prepared before use. The tablet is round, faintly 
yellow, marked BAI on one side and 2.3 on the other. The solution is colourless. One tablet 
for rectal suspension contains Lactose anhydrous 263 mg, lactose monohydrate 1.3 mg, 
riboflavin sodium phosphate (E101), crospovidone, colloidal silica and magnesium stearate.  
1ml solution contains: Sodium chloride 9 mg, methyl parahydroxybenzoate (E218), propyl 
parahydroxybenzoate (E216) and purified water.  
3. Pentasa enema (2016)
53
 Pentasa Enema is a rectal, 100 ml of a  colourless to faint yellow 
suspension containing 1 gm Mesalazine is an active ingredient used for the treatment of UC. 
Other excipients are disodium edetate, sodium metabisulphate, sodium acetate, hydrochloric 
acid (concentrated) and purified water.  
4. Predsol suppositories and enemas (2014)
54
 The active ingredient in PREDSOL is 
prednisolone as sodium phosphate, which is a type of glucocorticoid belonging to a group of 
medicines called corticosteroids. Used in the treatment of UC and Crohn’s disease. Each 
retension enema contains 20 mg/100 ml of prednisolone (as prednisolone sodium phosphate), 
sodium hydroxide, sodium phosphate-dibasic, sodium phosphate-monobasic, disodium 
edetate, Nipastat GL75 and water purified. Nipastat GL is a preservative which contains 
methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate, butyl 
hydroxybenzoate and isobutyl hydroxybenzoate.  
5. Predsol retention enema (2015)
55
 20 mg/100 ml rectal solution contains 20 mg of the 
active substance prednisolone as the sodium phosphate ester. Predsol retention enema 
CHAPTER 3                                                                                                                                                        LITERATURE REVIEW 
 
DEPARTMENT OF PHARMACEUTICS, S.B.C.P, SIVAKASI. Page 29 
 
belongs to a group of medicines called corticosteroids. Each 100 ml bottle contains 20 mg 
prednisolone as prednisolone sodium phosphate. The other ingredients are nipastat, disodium 
edetate, sodium acid phosphate, disodium phosphate anhydrous, sodium hydroxide and 
purified water.  
6. Entocort Enema (2016)
56
 It contains a medicine called budesonide. This belongs to a 
group of medicines called ‘corticosteroids’. They are used to reduce inflammation and ulcers 
in the large intestine and rectum. Entocort enema contains 2 mg of budesonide at a 
concentration of 0.02 mg of budesonide per ml of solution. The other ingredients are lactose 
anhydrous, polyvidone, riboflavin sodium phosphate, lactose monohydrate, magnesium 
stearate, colloidal anhydrous silica, sodium chloride, methyl parahydroxy benzoate (E218), 
propyl parahydroxybenzoate (E216) and water purified.  
7. Predonema Enema (2013)
57
 contains prednisolone sodium phosphate 22 mg: the Japanese 
Pharmacopoeia (J.P), carboxy vinyl polymer, disodium hydrogen phosphate hydrate, ethyl 
parahydroxybenzoate, butyl parahydroxybenzoate, disodium edetate hydrate and sodium 
hydroxide. This product occurs as a slightly viscous, colourless transparent solution. 
Identification code of package material is KP-009.  
8. Rowasa (2008)
58
 The active ingredient in Rowasa (mesalamine) rectal suspension enema, 
a disposable (60 mL) unit is mesalamine, also known as 5-aminosalicylic acid (5-ASA). 
Chemically, mesalamine is 5-amino-2-hydroxybenzoic acid. Each rectal suspension enema 
unit contains 4 gms of mesalamine. In addition to mesalamine the preparation contains 
carbomer 934P, edetate disodium, potassium acetate, potassium metabisulfite, purified water 
and xanthum gum.  
9. Predenema (2015)
59
 is a single dose retention enema for application into the rectum. Each 
single dose, disposable enema contains a rectal solution of 20 mg prednisolone, as 
prednisolone sodium meta-sulphobenzoate in 100 ml. prednisolone belongs to a group of 
medicines called corticosteroids which are used to reduce inflammation. As well as the active 
ingredient also contains disodium edetate, parahydroxy benzoates (E214, E216, E218) and 
purified water.  
10. Cortenema (2007)
60
 is a convenient disposable single dose hydrocortisone, 100 mg in an 
aqueous solution containing carbomer 934P, polysorbate 80, purified water, sodium 
hydroxide and methyl paraben 0.18% as preservative. 
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11. Entocort, Apulein
61
 is Budesonide 0.2 mg/ml Suspendol-S
TM 
rectal enema (Perrigo 
Paddock)
 
containing Budesonide, propylene glycol and Suspendol- S
TM 
syrup. Suspendol- 
S
TM
 is a semi-clear viscous liquid contains purified water, carboxypolymethylene (as 
thickening and suspending agent), polysorbate 80, simethicone, sodium hydroxide, methyl 
paraben and propyl paraben. 
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4. MATERIALS AND METHODS 
 
4.1. MATERIALS USED AND MANUFACTURERS  
 
Table No.6: Materials Used and Manufacturers  
 
S. No. Material Manufacturer 
1.  Prednisolone Tianjin Tianyao Pharma, China. 
2.  Riboflavin – 5 sodium phosphate Supriya Life Science, Mumbai 
3.  Microcrystalline cellulose (PH101 
and PH 112) 
Wei Ming pharmaceuticals, Taiwan. 
4.  Crospovidone Nanhang  industrial & co, China. 
5.  Maize starch Ridhi Sidhi Pharmaceyuical Pvt Ltd, New Delhi. 
6.  Colloidal silicon dioxide Wacker Silicones, Mumbai. 
7.  Lactose (DCL 21) Cabot sanmar Ltd, Chennai. 
8.  Lactose monohydrate DMV Fonterra excipients, Newzealand. 
9.  Magnesium stearate Amishi Drugs & Chemical, Gujarat. 
10.  Purified talc Gangotri inorganic (P) Ltd, Gujarat. 
11.  Sodium chloride 
Avantor Performance materials India ltd, 
Haryana. 
12.  Methyl hydroxybenzoate Rasula Pharmaceutical, Hyderabad. 
13.  Propyl hydroxybenzoate Alta Laboratories, Mumbai. 
14.  Sodium carboxy methyl cellulose Jalan cellulose Co Ltd, India. 
15.  Propylene glycol Manali Petrochemicals Ltd, Chennai. 
16.  Purified water  Andavar &Co, Chennai. 
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4.2. DRUG PROFILE 
4.2.1. PREDNISOLONE 
62-65
 
SYNONYMS : Metacortandralone. 
 Hydroretrocortine. 
Deltacortril. 
Meticortelone. 
 
IUPAC NAME : (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-
hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-
octahydro-6H-cyclopenta [a] phenanthren-3-one. 
 
MOLECULAR FORMULA : C21H28O5 
 
MOLECULAR WEIGHT : 360.45 gm/mol. 
 
STRUCTURAL FORMULA : 
 
PHYSICAL PROPERTIES : Solid, white to practically white crystalline powder, 
odourless. 
 
SOLUBILITY : Practically insoluble in water.  
Soluble 1 in 150 parts of ethanol.  
Very slightly soluble in water. 
  
MELTING POINT : 235
o
 C. 
 
DOSAGE FORMS : Oral solution, Suspension, Tablets, Enema, Eye drops, 
Injections and Ointments. 
 
DOSE : 20 mg. 
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DESCRIPTION : A glucocorticoid with the general properties of the 
corticosteroids. It is the drug of choice for all conditions 
in which routine systemic corticosteroid therapy is 
indicated, except adrenal deficiency states.  
 
MECHANISM OF ACTION : Prednisolone decreases inflammation by inhibition of 
migration of polymorphonuclear leukocytes and reversal 
of increased capillary permeability. It suppresses the 
immune system by reducing the activity and production 
of the lymphocytes and eosinophils. 
 
ABSORPTION : Readily absorbed from the GI tract with peak plasma 
concentrations after 1-2 hr (oral); initial absorption is 
affected by food. 
 
DISTRIBUTION : Inactivated as it crosses the placenta; enters the breast 
milk.  
 
METABOLISM : Prednisolone is a synthetic glucocorticoid that is used 
clinically for its anti-inflammatory properties. 
Prednisolone can diffuse passively across the cell 
membrane, where it binds to glucocorticoid receptors in 
the cytoplasm. Upon binding the glucocorticoid receptor 
(GR) dissociates from heat shock protein 90 and 
translocate into the nucleus. In the nucleus, GR dimers 
can bind to glucocorticoid response element (GRE) in the 
promoter region of anti-inflammatory genes, which 
activates their transcription of inflammatory mediators by 
binding to negative GRE (nGRE). GRs further interact 
with the transcription factors cAMP- responsive element 
binding protein and NF-kappa-B and inhibit their 
activation of inflammatory gene transcription. GRs also 
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recruit histone deacetylase 2 to inflammatory genes, 
which leads to DNA condensation at those loci, thus 
suppressing expression of those genes. 
 
EXCRETION : Via urine (as free and conjugated metabolites). 
 
PROTEIN BINDING : Very high (>90%). 
 
PHARMACODYNAMICS : Prednisolone is a synthetic glucocorticoid used as anti-
inflammatory or immunosuppressive agent. Prednisolone 
is indicated in the treatment of various conditions, 
including congenital adrenal hyperplasia, psoriatic 
arthritis, systemic lupus erythematosus, bullous dermatitis 
herpetiformis, seasonal or perennial allergic rhinitis, 
allergic corneal marginal ulcers, symptomatic sarcoidosis, 
idiopathic thrombocytopenic purpura in adults, leukemias 
and lymphomas in adults and UC. Glucocorticoids are 
adrenocortical steroids and it cause profound and varied 
metabolic effects. In addition, they modify the body's 
immune responses to diverse stimuli. 
BIOLOGICAL HALF-LIFE : 2-3 hrs. 
CLINICAL INDICATIONS : For the treatment of primary or secondary adrenocortical 
insufficiency, such as congenital adrenal hyperplasia, 
thyroiditis. Also used to treat psoriatic arthritis, 
rheumatoid arthritis, ankylosing spondylitis, bursitis, 
acute gouty arthritis and epicondylitis. Also indicated for 
treatment of systemic lupus erythematosus, pemphigus 
and acute rhematic carditis. Can be used in the treatment 
of leukemias, lymphomas, thrombocytopenia purpura and 
autoimmune hemolytic anemia.  
CONTRAINDICATIONS : Live vaccines; herpes simplex keratitis, systemic 
infections. 
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PRECAUTIONS : Patients with hypothyroidism, cirrhosis, UC, congestive 
heart failure, convulsive disorders, thrombo phlebitis, 
peptic ulcer elderly. Diabetes mellitus, hypertension, 
psychological disturbances, osteoporosis, pregnancy and 
lactation. Adrenal suppression and infection. May cause 
irreversible growth retardation, glaucoma, corneal 
perforation. Topical: Broken or infected skin. Not to be 
applied over large areas under occlusive dressings. 
 
DRUG INTERACTIONS : Increased requirement of insulin and oral 
hypoglycaemics. Actions blunted by barbiturates, 
phenytoin, rifampicin. Increased bioavailability with 
estrogens and oral contraceptives. Increases plasma 
salicylate levels. Increased risk of convulsions when used 
with ciclosporin, increased clearance by carbimazole or 
carbamazepine. Increased risk of GI bleeding and 
ulceration when used with NSAIDs. May decrease 
methotrexate clearance. 
 
PREGNANCY : There are no major human studies of prednisolone use in 
pregnant women, studies in several animals show that it 
may cause birth defects including increase cleft palate. 
Prednisolone should be used in pregnant women when 
benefits outweigh the risks and children born from 
mothers using prednisolone during pregnancy should be 
monitored for impaired adrenal function. 
 
LACTATION : Prednisolone is found in breast milk of mothers, who are 
taking Prednisolone. 
 
SIDE EFFECTS : Side effects with short term use include nausea and 
feeling tired.
 
More severe side effects include psychiatric 
problems, which may occur in about 5% of people. 
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Common side effects with long term use include bone 
loss, weakness, yeast infections and easy bruising.
 
While 
short term use in the later part of pregnancy is safe, use 
long term or early in early pregnancy is occasionally 
associated with harm to the baby. 
 
OVERDOSE : Treatment of acute overdose includes immediate gastric 
lavage or emesis followed by supportive and 
symptomatic therapy. For chronic overdose, the dosage of 
prednisolone may be reduced temporarily or introduce 
alternate day treatment. 
 
APPLICATIONS : It also suppresses the immune system. Prednisolone is 
used as an anti-inflammatory or an immunosuppressant 
medication. Prednisolone treats many different conditions 
such as allergic disorders, skin conditions, UC, arthritis, 
lupus, psoriasis and breathing disorders. 
 
STORAGE : Stored at 20 – 25°C. 
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4.3. EXCIPIENTS PROFILE 
Table No. 7 
4.3.1. RIBOFLAVIN-5-SODIUM PHOSPHATE
66 
S. No. Properties Description 
1 Non- proprietary name BP: Riboflavin – 5 sodium phosphate. 
2 Synonyms Vitamin B2, Vactochrome, Lactoflavin, Vitamin G. 
3 Chemical name 
7,8-Dimethyl-10-[(2S,3S,4R)-2,3,4,5-
tetrahydroxypentyl]benzo[g]pteridine-2,4-dione. 
4 Molecular structure 
 
5 Molecular formula C17H20N4O6 
6 Molecular weight 376.37 gm/mol. 
7 Melting point >300°C. 
8 Description 
Nutritional factor found in milk, eggs, malted barley, 
liver, kidney, heart, and leafy vegetables. The richest 
natural source is yeast. It occurs in the free form only 
in the retina of the eye, in whey, and in urine; its 
principal forms in tissues and cells are as flavin 
mononucleotide and flavin-adenine dinucleotide. 
9 Solubility 0.1 gm/mL, clear, orange-yellow. 
10 Functional category 
Coenzyme for a number of oxidative enzymes 
including NADH DEHYDROGENASE. 
11 Application 
Phototherapy, treatment of neonatal jaundice and 
a supplement of coenzyme.  
12 Storage 2-8°C. 
13 Stability Stable, incompatible with strong oxidizing agents. 
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Table No. 8 
4.3.2. MICROCRYSTALLINE CELLULOSE
67 
 
  
S. No. Properties Description 
1 Non- proprietary name 
BP: Microcrystalline cellulose. 
PhEur: cellulosum microcrystallinum. 
2 Synonyms 
Avicel PH, celex, cellulose gel, cellulosum 
microcrystallinum, emcocel, fibrocel, pharmacel, 
vivace, E46. 
3 Chemical name Cellulose.  
4 Molecular structure 
 
5 Molecular weight Approximately 36000. 
6 Melting point 260 to 270
o
C. 
7 Density 1.512 to1.668 gm/cm
3
. 
8 Description 
Microcrystalline cellulose is purified, white, odourless, 
tasteless, crystalline powder composed of porous 
particles. 
9 Solubility 
Insoluble in water, organic solvent,  
Slightly soluble in 5 % w/v NaOH solution. 
10 Functional category 
Adsorbent, suspending agent, tablet, capsule 
diluent and tablet disintegrant. 
11 Application 
Microcrystalline cellulose is used in pharmaceutical 
industries primarily as binder/diluents for tablets and 
capsules formulation where in both wet granulation 
and direct compression process and also used for 
lubricant, disintegrant properties. It is also used in 
cosmetics and food products. 
12 Storage It should be stored in well closed container. 
13 Stability 
Microcrystalline cellulose is a stable, though 
hygroscopic material. 
14 Incompatibilities 
Microcrystalline cellulose is incompatible with strong 
oxidizing agents. 
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Table No. 9 
4.3.2.1. Properties of some commercially available grades of Microcrystalline Cellulose 
 
Grade 
Nominal mean 
particle size (µm) 
Particle size analysis 
Moisture    
content (%) 
Mesh size 
Amount 
retained (%) 
Avicel PH-102 100 
60 8.0 
5.0 
200 45.0 
Avicel PH-112 100 60 8.0 1.5 
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Table No. 10 
4.3.3. CROSPOVIDONE
67 
S. No. Properties Description 
1 Non- proprietary name 
BP  : Crospovidone. 
PhEur: Crospovidon. 
2 Synonyms 
Cross linked polymer; kollidon CL; polyplasdone 
XL-10; polyvinylpolypyrrolidone. 
3 Chemical name 1-ethenyl-2-pyrrolidinone Homopolymer. 
4 Molecular structure 
 
5 Molecular weight >1000000. 
6 Moisture content 60% w/w. 
7 Density 1.22 gm/cm
3
 
8 Description 
Crospovidone is a white to creamy-white, finely 
divided, free-flowing, practically tasteless, odorless, 
hygroscopic powder. 
9 Solubility 
Partially Insoluble in water and most common 
organic solvents. 
10 Functional category Tablet disintegrant. 
11 Application 
Crospovidone is a water insoluble tablet disintegrate 
and dissolution agent used at 2-5% concentration in 
tablet prepared by direct compression or wet and dry 
granulation method. 
12 Storage 
It is a hygroscopic material. The bulk material 
should be stored in a well- closed container in a 
cool, dry place. 
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Table No. 11 
4.3.4. MAIZE STARCH
67 
S. No. Properties Description 
1 Non- proprietary name Maize starch. 
2 Synonyms Amido, amidon, amilo, amylum, melojel. 
3 Chemical name 
Maize starch, potato starch, rice starch, tapioca starch, 
wheat starch. 
4 Molecular structure 
 
5 Molecular formula (C6H10O5)n Where n = 300 – 1000 
6 Molecular weight 50 000 – 160000 
7 Description 
Starch occurs as an odourless and tasteless, fine, white-
colored powder comprising very small spherical or 
ovoid granules whose size and shape are characteristic 
for each botanical variety. 
8 Solubility Soluble in water when heated. 
9 Functional category 
Glidant; tablet and capsule diluent; tablet and capsule 
disintegrant; tablet binder. 
10 Application 
Starch is used as an excipient primarily in oral solid-
dosage formulations where it is utilized as a binder, 
diluent, and disintegrant. 
11 Storage 
Store the corn starch in a sealed container and in a cool, 
dry place. 
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Table No. 12 
4.3.5. COLLIODAL SILICON DIOXIDE
67,68 
S. No. Properties Description 
1 Non-proprietary name 
 BP: Colloidal anhydrous silica. 
USPNF: colloidal silicon dioxide. 
2 Synonyms 
Aerosil, cab-o-sil, cab-o-sil M-5P, colloidal silica, fumed 
silica, light anhydrous silicic acid, silicic anhydride and 
silicon dioxide fumed. 
3 Chemical name Silica. 
4 Molecular structure SiO2 
5 Molecular weight 60.08 gm/mol. 
6 Bulk Density 0.029–0.42 gm/cm3 
7 Tapped Density 0.05-0.12 gm/cm
3
 
8 Description 
Colloidal silicon dioxide is sub microscopic fumed silica 
with a particle size of about 15nm. It is a light, loose, 
white coloured, odourless, tasteless, non-gritty 
amorphous powder. 
9 Solubility 
Practically insoluble in organic solvents, water and acids 
except hydrofluoric acid, soluble in hot solutions of alkali 
hydroxide forms a colloidal dispersion with water. 
10 Functional category 
Adsorbent, anticaking agent, glidant, suspending agent, 
tablet disintegrant and viscosity increasing agent. 
11 Application 
Colloidal silicon dioxide is widely used in 
pharmaceuticals, cosmetics and food products. 
12 Storage 
Colloidal silicon dioxide powder should be stored in a 
well-closed container. 
13 Incompatibilities Incompatible with diethylstilbestrol preparation. 
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Table No. 13 
4.3.6. LACTOSE MONOHYDRATE
67, 69 
S. No. Properties Description 
1 Non- proprietary name 
BP : Lactose monohydrate.  
USPNF : Lactose monohydrate. 
2 Synonyms 
Fast-flo, (β-D-galactosido)-D-glucose, lactochem, 
microtose, milk sugar, pharmatose, saccharumlactis. 
3 Chemical name 
β-D-Galactopyranosyl-(1,4)--D-glucopyranose 
monohydrate. 
4 Molecular structure 
  
5 Molecular weight 342.3 gm/mol. 
6 Melting point 201-202
o
C. 
7 Density 1.545 gm/cm
3
 
8 Description 
Lactose occurs as white to off-white crystalline particles 
powder. 
9 Solubility Chloroform, ethanol, ether are practically insoluble. 
10 Functional category 
Binding agent; diluents for dry-powder inhalers; tablet 
binder; tablet and capsule diluents. 
11 Application 
Lactose is widely used in tablets and capsules as filler. 
And also used in dry-powder inhalation as a diluents. 
12 Storage Lactose should be stored in a well closed container. 
13 Incompatibilities 
Lactose is incompatible with aminoacids, aminophylline 
and amphetamines. 
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Table No. 14 
4.3.7. MAGNESIUM STEARATE
67 
S. No. Properties Description 
1 Synonyms 
Magnesium octadecanoate, stearic acid, magnesium 
salt. 
2 Chemical name Octadecanoate stearic acid magnesium salt. 
3 Molecular structure [CH3 (CH2 )16 COO]2 Mg. 
4 Molecular weight 591.27 gm/mol. 
5 Melting point 88
o
C. 
6 Description 
It occurs as a fine, white precipitated or milled 
impalpable powder with a faint odour and a 
characteristic taste. 
7 Solubility 
Practically insoluble in ethanol, ether and water, 
slightly soluble in warm benzene and warm ethanol 
(95 %). 
8 Functional category Lubricant. 
10 Application 
It is widely used in cosmetics, food, pharmaceutical 
formulations. It is primarily used as lubricant in 
capsule and tablet manufacture at concentrations 
between 0.2-5.0%. 
11 Stability 
It is stable and should be stored in a well closed 
container in a cool and dry place. 
12 Incompatibilities It is incompatible with strong acids, alkalis and iron. 
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Table No. 15 
4.3.8. PURIFIED TALC
67 
S.No. Properties Description 
1 Synonyms 
Altalc; E553; hydrous magnesium calcium silicate, 
luzenac pharma, magsilosmanthus, magsil Star, 
powdered talc, purified french chalk, soapstone, steatite 
superior. 
2 Chemical name Talc. 
3 Molecular formula Mg6 (Si2O5)4(OH)4 
4 Molecular weight 379.3 gm/mol. 
5 Melting point 93
o
C. 
6 Description 
Purified talc is a very fine, white to greyish-white, 
odourless, impalpable, unctuous, crystalline powder. It 
adheres readily to the skin and is soft to touch and free 
from grittiness. 
7 Solubility 
Practically insoluble in dilute acids and alkalis, organic 
solvents and water. 
8 Functional category 
Anti-caking agent, glidant, tablet and capsule diluent, 
tablet and capsule lubricant. 
9 Application 
It is widely used as a dissolution retardant in the 
development of controlled release products. Purified talc 
is also used as lubricant in tablet formulations, coating 
for pellets and as an adsorbent in topical preparations. 
Purified talc is used as a dusting powder and also used 
to clarify liquids and it is mainly used in food and 
cosmetic products as a lubricant. 
10 Incompatibilities Incompatible with quaternary ammonium compounds. 
11 Storage Stored at well closed container. 
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Table No. 16 
4.3.12. SODIUM CHLORIDE
67 
S. No. Properties Description 
1 Synonyms Salt, Table salt, Halite, Saline. 
2 Chemical name Sodium chloride. 
3 Molecular formula NaCl 
4 Molecular weight 58.44 gm/mol. 
5 Boiling point 1465°C. 
6 Density 1.199 gm/mL at 20°C 
7 Melting point 800.7°C 
8 pH 6.7 to 7.3; its aqueous solution is neutral. 
9 Description 
A white crystalline solid. Commercial grade 
usually contains some chlorides of 
calcium and magnesium which absorb moisture 
and cause caking. 
10 Solubility Soluble in water, slightly soluble in ethanol. 
11 Functional category 
Channeling agent, and as an osmotic agent, 
isotonic solutions. 
12 Stability Stable. 
13 Incompatibility Incompatible with strong oxidizing agents. 
14 Storage Keep container tightly closed. 
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Table No. 17 
4.3.13. SODIUM CARBOXY METHYL CELLULOSE
67,70 
S. No Properties Description 
1 Synonyms 
Cellulose gum, carboxy methyl cellulose, 
sodium cellulose glycolate. 
2 Chemical name Carboxymethyl cellulose. 
3 Molecular structure 
  
4 Molecular formula Variable. 
5 Molecular weight Variable. 
6 Viscosity 5mPa.s-8000mPa.s. 
7 Density 1.6 gm/cm
3
 
8 Melting point 274°C. 
9 Description 
Sodium carboxylmethyl cellulose is odorless, tasteless 
and nontoxic white or yellowish powder. 
10 Solubility 
Favorable water solubility, insoluble in organic 
solvents such as methanol, ethanol, acetone, 
chloroform and benzene. 
11 Functional category 
Bulking agent, emulsifier, firming agent, gelling agent, 
glazing agent, humectant, stabilizer, thickener. 
12 Applications 
CMC is used in food under the E number E466 as a 
viscosity modifier or thickener, and to stabilize 
emulsions in various products including ice cream. It is 
also a constituent of many non-food products, such as 
toothpaste, laxatives, diet pills, water-based paints, 
detergents, textile sizing, and various paper products. 
13 Stability Stable. 
14 Incompatibility Incompatible with strong oxidizing agents. 
15 Storage Stored at room temperature. 
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Table No. 18 
4.3.9. PROPYLENE GLYCOL
67 
S. No. Properties Description 
1 Synonyms 
Dihydroxypropane, 2-hydroxypropanol, methylethylene 
glycol, methyl glycol, propane-1, 2-diol. 
2 Chemical name 1, 2-Propanediol. 
3 Molecular structure 
 
4 Molecular weight 76.09 gm/mol. 
5 Boiling point 188
o
C. 
6 Description 
Propylene glycol is a clear, colourless, viscous, s 
odourless liquid with a sweet, slightly acrid taste 
resembling that of glycerin. 
7 Solubility 
Miscible with acetone, chloroform, ethanol (95%) 
glycerin and water; soluble at 1 in 6 parts of ether. 
8 Functional category 
Antimicrobial preservative, disinfectant, humectants, 
plasticizer, solvent, stabilizer for vitamins, water-miscible 
co-solvent. 
9 Application 
Propylene glycol is widely used as a solvent, extractant 
and preservative in a variety of parenteral and  
nonparenteral pharmaceutical formulations. 
10 Storage 
Propylene glycol is hygroscopic and should be stored 
in a well-closed container, protected from light, in a 
cool, dry place. 
11 Incompatibilities 
Propylene glycol is incompatible with oxidizing 
reagent such as potassium permanganate. 
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Table No. 19 
4.3.10. METHYL HYDROXYBENZOATE
67 
S. No. Properties Description 
1 Synonyms 
4-hydroxybenzoic acid methyl ester, methyl p-
hydroxybenzoate. 
2 Chemical name Methyl-4-hydroxybenzoate. 
3 Molecular structure 
  
 
4 Molecular formula C8H8O3 
5 Molecular weight 152.15 gm/mol. 
6 Description 
Methyl hydroxybenzoate occurs as colourless crystals or 
a white crystalline powder. It is odourless or almost 
odourless and has a slight burning taste. 
7 Solubility Soluble in water when heated. 
8 Functional category Antimicrobial preservative. 
9 Applications 
Methyl hydroxybenzoate is widely used as an 
antimicrobial preservative in cosmetics, food products, 
and pharmaceutical formulations. It may be used either 
alone or in combination with other parabens or with 
other antimicrobial agents. In cosmetics, methyl 
hydroxybenzoate is the most frequently used 
antimicrobial preservative. 
10 Storage Stored at well closed container. 
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Table No. 20 
4.3.11. PROPYL HYDROXYBENZOATE
67 
S. No. Properties Description 
1 Synonyms 
4-Hydroxybenzoesäurepropylester, propyl 
paraben, propyl p-hydroxybenzoate, propyl 
parahydroxybenzoate, nipasol, E216. 
2 Chemical name Propyl 4-hydroxybenzoate. 
3 Molecular structure 
  
4 Molecular formula  C10H12O3 
5 Molecular weight 180.2 gm/mol. 
6 Density 1.06 gm/cm³ 
7 Melting point  96 to 99°C 
8 Description 
Propyl hydroxybenzoate occurs as colourless 
crystals or a white crystalline powder. It is 
odourless or almost odourless and has a slight 
burning taste. 
9 Solubility Soluble in water when heated. 
10 Functional category Anti-fungal preservation agent. 
11 Applications 
It is a preservative typically found in many water-
based cosmetics, such as creams, lotions, 
shampoos and bath products. 
12 Storage Stored at well closed container. 
 
  
 
 
 
 
 
 
 
LIST OF EQUIPMENTS/ 
INSTRUMENTS 
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         4.4. List of Equipments / Instruments 
 
Table No. 21: List of Equipments / Instruments and Suppliers 
 
S. No. Instruments Manufacturers/Suppliers 
1 Electronic balance Adventurer Mettler Toleda 
2 Bulk density apparatus Thermonik, Campbel Electronics 
3 Electro Magnetic sieve shaker Electro Pharma 
4 Vernier calliper Absolute digimatic, Mitutoyo 
5 Monsanto Hardness Tester Tab-Machines 
6 Hot Plate Pathak electrical works 
7 Motor Blender Remi Motor 
8 Moisture balance Citizen 
9 pH Meter Digisun Electronics 
10 Melting point apparatus Lab India 
11 Ultra Sonicator Lab man Scientific Instruments 
12 Viscosity testing apparatus Brook field Dv-E viscometer, Lab india 
13 Hot air oven Pathak electrical works 
14 Friability test apparatus Electro Lab 
15 Disintegration tester Electrolab,ED-21, India 
16 Dissolution apparatus (Disso 2000) Lab India dissolution test apparatus 
17 UV Spectrophotometer Shimadzu  
18 FTIR Spectrophotometer 8300 Perkin Elmer 
19 8-Station punching machine Accura 
20 Stability chamber Thermo lab 
 
 
  
 
 
 
 
 
 
 
 
METHODOLOGY 
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4.5. METHODOLOGY 
 
4.5.1. PREFORMULATION STUDIES
71-73
 
Preformulation may be described as the process of optimizing a drug through 
determination of those physical and chemical properties considered important in the 
formulation of a stable, effective and safe dosage form. The possible interactions with the 
various components intended for use in the final drug product are also considered. It is an 
effort that encompasses the study of such parameters as dissolution, polymorphic forms and 
crystal size and shape, pH profile of stability and drug – excipients interactions, which may 
have a profound effect on a drug’s physiological availability and physical and chemical 
stability. Preformulation involves the application of biopharmaceutical principles to the 
physicochemical parameters of drug substance are characterized with the goal of designing 
optimum drug delivery system.  
Before beginning the formal preformulation programs we must consider the following 
factors, 
1. The amount of drug available. 
2. The physicochemical properties of the drug already known. 
3. Therapeutic category and anticipated dose of compound. 
4. The nature of information, a formulation should have or would like to have. 
Importance  
There are critical differences between companies at the detailed level of knowledge 
and their ability to learn before doing. 
1. Knowledge of the underlying variables and their relationship to performance. 
2. Knowledge of the future manufacturing environment and the new variables 
introduced by that environment. 
3. Part of the new drug development process. 
Scope 
Use of preformulation parameters maximizes the chances in formulating an 
acceptable, safe, efficacy and stable product. At the same time provides the basis for 
optimization of drug product quality. 
Some of the important parameters evaluated during preformulation studies are 
following 
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 Physicochemical evaluation of drug molecule 
 Description 
 Solubility 
 Melting point 
 Particle size determination 
 Loss on drying 
 Flow properties 
 Compatibility studies of the drug with excipients 
 
4.5.1.1. DESCRIPTION 
It is the initial evaluation during preformulation studies which assess the colour and 
taste of the substance. This was only a descriptive test. 
 
4.5.1.2. SOLUBILITY
74
 
Aqueous solubility is an important physicochemical property of drug substance, 
which determines its systemic absorption and in turns its therapeutic efficacy.  
 
Table No. 22: Solubility Specifications 
Descriptive terms Approximate volume of solvent 
in millilitres per gram of solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1,000 
Very slightly soluble From 1,000 to 10,000 
Practically insoluble More than 10,000 
 
 
4.5.1.3. MELTING POINT
74 
The temperature at which the first particle of the substance completely melts is 
regarded as melting point of the substance. The temperature at which the first particle start to 
melt and last particle completely melts is regarded as melting range. Melting point of 
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Prednisolone was conducted by using melting point apparatus. One capillary tube was filled 
with pure Prednisolone and placed into the melting point apparatus. The temperature was 
noted at the time of the substance completely melts. 
 
4.5.1.4. LOSS ON DRYING
74
 
The loss on drying test is designed to measure the amount of water and volatile 
matters in a sample when the sample is dried under specified conditions. Loss on drying of 
prednisolone was measured by using moisture balance. Approximately weighed 1 gm of 
prednisolone and placed into a plate on the moisture balance. The temperature was set to be 
60
0
C. Then the moisture content present in the Prednisolone was measured in percentage. 
 
4.5.1.5. FLOW PROPERTIES 
 
1. Angle of Repose 75 
Angle of repose is defined as the maximum angle possible between the surface of the 
pile of the powder and horizontal plane. The angle of repose of the powder or granules was 
determined by fixed funnel method. To assess the flow property of the powder granules, the 
height of the funnel was adjusted in such a way that the tip of the funnel just touches the apex 
of the heap of the powder above a paper that was placed on a flat horizontal surface. 
Accurately weighed prednisolone was taken in a beaker. It was allowed to flow through the 
funnel freely on the surface of the paper to form a cone shaped pile. The diameter of the cone 
(d) and the height (h) of the pile was noted. From the diameter, radius (r) was calculated. The 
angle of repose (θ) was calculated using the following formula. 
 
θ = tan –1(h/r) 
Where,  
                θ = Angle of repose 
                    h = Height of the cone 
                    r = Radius of the cone 
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Table No. 23: Angle of repose as an Indication of Powder Flow Property 
S. No. Type of flow 
Angle of repose 
(degree) 
1 Excellent 25– 30 
2 Good 31 – 35 
3 Fair 36 – 40 
4 Passable 41 – 45 
5 Poor 46 – 55 
6 Very  poor 56 – 65 
7 Very very poor >66 
 
 
2. Density (gm/cm3)76 
a) Bulk Density (Db) 
Weighed quantity of prednisolone were transferred into a 50 ml measuring cylinder 
without tapping during transfer the volume occupied by the granules was measured. Bulk 
density (Db) was measured by using formula. 
Db= m/Vo 
Where, 
Db = bulk density 
m = mass of the blend 
           Vo = untapped volume 
 
b) Tapped Density (Dt) 
Weighed quantity of Prednisolone was taken into a 50 ml measuring cylinder. Then 
cylinder was subjected to 50 taps in tapped density tester (Electro lab USP ІІ). According to 
the U.S.P, the blend was subjected for 50 taps; the percentage volume variation was 
calculated by using the following formula. 
Dt = m/Vt 
Where, 
Dt = tapped density 
M = mass of the blend 
Vt = Tapped volume 
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3. Measurement of powder compressibility77 
 
a) Compressibility Index 
The compressibility index is a measure of the propensity of a powder to consolidate. 
As such, it is a measure of the relative importance of inter-particular interaction. The 
compressibility index of the Prednisolone was determined by the Carr’s compressibility index 
with the help of bulk density and tapped density value using the following formula.  
 
Compressibility index 
                           
              
     
 
 The values and its flow properties are given in the Table No.24. 
 
b) Hausner’s Ratio 
The Hausner’s ratio is a number that is correlated to the flowability of a powder or 
granular material. Hausner’s ratio of the Prednisolone was determined by the ratio of tapped 
density and bulk density using the following formula.  
 
Hausner’s ratio =   
                  
            
 
 
The values and its flow properties are given in the Table No.24. 
Table No. 24: Compressibility Index, Hausner’s Ratio and as an Indication of 
Powders/Granules Flow 
S. No. 
Compressibility 
Index ( % ) 
Type of flow 
Hausner’s 
ratio 
1 1 –  10 Excellent 1.00-1.11 
2 11– 15 Good 1.12-1.18 
3 16 – 20 Fair 1.19-1.25 
4 21 – 25 Passable 1.26-1.34 
5 26 – 31 Poor  1.35-1.45 
6 32 – 37 Very poor 1.46-1.59 
7 >38 Very very poor >1.60 
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4.5.1.6. PARTICLE SIZE DISTRIBUTION
78 
In case of tablets, size influences the flow and the mixing efficiency of powders and 
granules. Size can also be a factor in stability. Fine materials are relatively more open to 
attack from atmospheric oxygen, the humidity and interacting excipients than coarse 
materials. 
Particle size distribution of the Prednisolone was estimated by sieving method using 
magnetic sieve shaker. The sieves are stacked on top of one another in ascending degrees of 
coarseness. 10 gm of Prednisolone was placed on the top sieve. The nest of sieves was 
subjected to a standard period of agitation. The weight of material retained on each sieve was 
accurately determined. Percentage of powder retained on each sieve was calculated by using 
the following formula.  
 
                    
                            
            
     
 
Table No. 25: Classification of Sample was based on the Percentage of Sample Retained 
or passed on Test Sieves 
S. No. Nature of sample Result of determination 
1 Coarse powder 
NLT 95% of the sample mass pass through #14 
and NMT 40% pass through #36 
2 Moderately coarse powder 
NLT 95% of the sample mass pass through #25 
and NMT 40% pass through #60 
3 Moderately fine powder 
NLT 95% of the sample mass pass through #36 
and NMT 40% pass through #100 
4 Fine powder 
NLT 95% of the sample mass pass through #100 
and NMT 40% pass through #150 
5 Very fine powder 
NLT 95% of the sample mass pass through #150 
and NMT 40% pass through #200 
6 Super fine powder 
NLT 90% by number of particles are less than 
10µm 
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4.5.1.7. PHYSICAL DRUG-EXCIPIENTS COMPATIBILITY STUDIES
79 
In the tablet dosage form the drug is in intimate contact with one or more excipients, 
the latter could affect the stability of the drug. Knowledge of drug- excipients interactions 
therefore is very useful to the formulators in selecting appropriate excipients. 
Compatibility studies were performed by preparing blend of different excipients with 
drug and stored at 40
o
C ± 2
o
C/75 ± 5% RH for three weeks. The initial state of mixture was 
noted and further evaluation for the possible occurrence of any changes was performed every 
week up to 3
rd
 week. The drug excipients compatibility in physical observation protocol is 
given in Table No. 26. 
 
Table No. 26: Drug: Excipients Compatibility study Protocol 
 
S. No. Composition 
Quantity 
(gm) 
Ratio 
1 Prednisolone 1.0 1:0 
2 
Prednisolone + Riboflavin-5- sodium 
phosphate 
2.0 1:1 
3 Prednisolone + Microcrystalline cellulose 2.0 1:1 
4 Prednisolone + Crospovione 2.0 1:1 
5 Prednisolone + Maize starch 2.0 1:1 
6 Prednisolone + Colloidal anhydrous silica 1.5 1:0.5 
7 Prednisolone + Lactose (DCL 21) 1.5 1:0.5 
8 Prednisolone + Lactose monohydrate 1.5 1:0.5 
9 Prednisolone + Methyl hydroxylbenzoate 1.5 1:0.5 
10 Prednisolone + Propyl hydroxybenzoate 1.5 1:0.5 
11 Prednisolone + Magnesium stearate 1.5 1:0.5 
12 Prednisolone + Purified talc 1.5 1:0.5 
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4.5.2. FORMULATION OF PREDNISOLONE DISPERSIBLE TABLETS 
 
4.5.2.1. SELECTION OF EXCIPIENTS 
 Excipients used in the present study were selected according to innovator excipient 
list. Excipients include Riboflavine-5- sodium phosphate, microcrystalline cellulose (PH102 
and PH112), crospovidone, maize starch, colloidal anhydrous silica, lactose (DCL21), lactose 
monohydrate, methyl hydroxybenzoate, propyl hydroxybenzoate, magnesium stearate and 
purified talc in the tablet core. Methyl hydroxybenzoate, propyl hydroxybenzoate, propylene 
glycol, sodium chloride, sodium carboxy ethyl cellulose and purified water are used for the 
vehicle solution. 
 
4.5.2.2. PROCEDURE: 
Three methods were used for the formulation of Prednisolone dispersible tablets: 
1. Direct compression method 
2. Wet granulation method 
3. Slugging method 
Tablets were prepared by using direct compression for the formulations F1 – F3. Wet 
granulation is used for the formulation F4 and F5. Slugging method is used in formulation 
F6. The details of the formulation along with the excipients in quantities and in percentages 
used are mentioned in Table No.27 & 28. 
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Table No. 27: Formulations of Prednisolone Dispersible Tablets 
 
S. 
No. 
Ingredients (mg) 
Quantity of ingredients  (mg/tab) 
Direct compression 
Wet 
granulation 
Slugging 
method 
F1 F2 F3 F4 F5 F6 
1 Prednisolone 20 20 20 20 20 20 
2 
Riboflavine -5 sodium 
phosphate 
3 3 3 3 3 3 
3 
Microcrystalline cellulose 
(PH112) 
40 40 45 - - 40 
4 
Microcrystalline cellulose 
(PH102) 
- - - 40 40 - 
5 Crospovidone 15 15 20 15 35 15 
6 Maize starch 4 4 7 28 28 4 
7 Maize starch Paste - - - 2 2 - 
8 Colloidal anhydrous silica 6 8 12 2 2 6 
9 Lactose (DCL 21) 36 36 37 - - 36 
10 Lactose Monohydrate - - - 34 34 - 
11 Methyl  hydroxybenzoate - - - 0.4 0.4 - 
12 Propyl  hydroxybenzoate - - - 0.1 0.1 - 
13 Magnesium stearate 4 4 4 4 4 4 
14 Purified talc 2 2 2 1.5 1.5 2 
  Total weight (mg) 130 132 150 150 170 130 
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Table No. 28: Percentage of Ingredients used in Formulations 
 
S. No. Ingredients 
 Quantity of ingredients (%) 
Direct compression Wet granulation 
Slugging 
method 
F1 F2 F3 F4 F5 F6  
1 Prednisolone 15.38 15.15 13.33 13.33 11.76 15.38 
2 
Riboflavin -5 sodium 
phosphate 
2.3 2.27 2 2 1.76 2.3 
3 
Microcrystalline cellulose 
(PH112) 
30.77 30.3 30 - - 30.77 
4 
Microcrystalline cellulose 
(PH102) 
- - - 26.66 23.52 - 
5 Crospovidone 11.53 11.36 13.33 10 20.58 11.53 
6 Maize starch 3.07 3.03 4.66 18.66 16.47 3.07 
7 Maize starch paste - - - 1.33 1.17 - 
8 Colloidal anhydrous silica 4.61 6.06 8 1.33 1.17 4.61 
9 Lactose (DCL 21) 27.69 27.27 24.66 - - 27.69 
10 Lactose monohydrate - - - 22.66 20 - 
11 Methyl  hydroxybenzoate - - - 0.26 0.23 - 
12 Propyl  hydroxybenzoate - - - 0.07 0.05 - 
13 Magnesium stearate 3.07 3.03 2.66 2.66 2.35 3.07 
14 Purified talc 1.53 1.51 1.33 1 0.88 1.53 
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DIRECT COMPRESSION METHOD 
 
Weighing 
The specified quantity of prednisolone and other all excipients were accurately 
weighed. 
 
Sifting 
Sift the following materials individually Prednisolone and micro crystalline cellulose 
(PH112) were sifted using 30 # mesh. Riboflavin -5- sodium phosphate, crospovidone, maize 
starch, and lactose (DCL21) were sifted through 40 # mesh. Colloidal anhydrous silica was 
passed through 60 # mesh sieve. The sifted powders were mixed in a polythene bag for ten 
minutes. 
 
Lubrication 
The above sifted granules were lubricated using magnesium stearate and purified talc, 
which was sifted through 60 # mesh size. Mix it for 5 minutes in a polythene bag. 
 
Compression 
Then final lubricated blend was compressed at an average weight of 130 mg, 132 mg 
and 150 mg using punch size 7.1 mm and 8 mm. 
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FORMULATION FLOWCHART OF DIRECT COMPRESSION METHOD 
(F1-F3) 
 
  
  
 
 
 
  
  
  
  
 
  
  
 
  
 
 
 
 
 
 
 
 
SIFTING 
 MIXING 
 
LUBRICATION 
 
COMPRESSION 
 
  Sifted # 30 mesh 
   Sifted 40 # mesh 
Mixed for 10 min. 
WEIGHING 
 
Prednisolone, riboflavin -5-sodium 
phosphate, microcrystalline cellulose 
(PH112), crospovidone, maize starch, 
colloidal anhydrous silica, lactose 
(DCL 21), magnesium stearate and 
purified talc. 
 
 
 
 
Prednisolone and micro crystalline 
cellulose (PH112) 
Riboflavin -5- sodium phosphate, 
crospovidone, maize starch and lactose 
(DCL21). 
Colloidal anhydrous sillica.    Sifted 60 # mesh 
Prednisolone, riboflavin -5-sodium 
phosphate, microcrystalline cellulose 
PH112, crospovidone, maize starch, 
colloidal anhydrous silica, lactose 
(DCL 21). 
 
 
 
 
Magnesium stearate and purified talc. 
    Mixed for 5 min. 
The powder blends were compressed 
into tablets and collected. 
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WET GRANULATION METHOD 
 
Weighing 
The specified quantity of prednisolone and other all excipients were accurately 
weighed. 
 
Sifting 
Individually prednisolone and maize starch were sifted using 60 # mesh. Riboflavin -
5- sodium phosphate, crospovidone, microcrystalline cellulose (PH 102) and lactose 
monohydrate were sifted through 40 # mesh. Colloidal anhydrous silica was passed through 
60 # mesh sieve. The sifted powders were mixed in a polythene bag for ten minutes. 
 
Binder preparation 
The binder solution of starch mucilage paste was prepared by maize starch in purified 
water having methyl hydroxybenzoate and propyl hydroxybenzoate under stirring condition.  
 
Granules preparation 
The prepared mucilage was added slowly to the dry mixed powder and granulated 
using kneading method. The wet mass was dried at a temperature of 60
o
C until the LOD (loss 
on drying) of granules is reached less than 1%. The dried granules were sifted through 20# 
mesh. 
 
Lubrication 
The above dried granules were lubricated using magnesium stearate and talc was 
sifted through 60 # mesh size. Mixed for 5 minutes in a polythene bag. 
 
Compression 
Then final lubricated blend was compressed at an average weight of 150 mg (F4) and 
170 mg (F5) using the punch size of 8 mm. 
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FORMULATION FLOWCHART OF WET GRANULATION METHOD 
(F4 AND F5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
BINDER 
PREPARATION 
 
MIXING 
 
WEIGHING 
 
Microcrystalline cellulose (PH102), 
maize starch, lactose monohydrate 
 
 
 
 
Starch paste contains methyl 
hydroxybenzoate and propyl 
hydroxybenzoate 
 
 
 
 
WET 
GRANULATION 
PREPARATION 
 
Granules prepared by adding starch 
paste. 
 
 
 
 
Dried granules + Prednisolone and 
other excipients 
 
 
 
 
 Dried at 60
o
C for 2 
hrs. 
LUBRICATION 
 
COMPRESSION 
 
Magnesium stearate and purified talc. 
The granules were compressed into 
tablets and collected. 
 
    Mixed 10 min. 
    Mixed 5 min. 
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SLUGGING METHOD 
 
Weighing 
The specified quantity of prednisolone and other all excipients were accurately 
weighed. 
 
Sifting 
Individually Prednisolone and micro crystalline cellulose (PH112) were sifted using 
30 # mesh. Riboflavine -5- sodium phosphate, crospovidone, maize starch, and lactose 
(DCL21) were sifted through 40 # mesh. Colloidal anhydrous silica was passed through 60 # 
mesh sieve. The sifted powders were mixed in a polythene bag for ten minutes. 
 
Lubrication 
The above sifted granules were lubricated using Magnesium stearate and purified talc 
which is sifted through 60 # mesh size mix for 5 minutes in a polythene bag. 
 
Compression 
Then final lubricated blend is compressed using the large punch size of 20 mm. 
 
Slugging 
 The compressed tablets were crushed into granules using mortar and pestle. Those 
granules were passed through initially by 16 # mesh then by 20 # mesh and finally passed 
through 30# sieve mesh to get uniformed granules. 
 
Re-compression 
 The collected granules were again compressed at an average weight of 130 mg using 
the punch size of 7.1 mm. 
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            FORMULATION FLOWCHART OF SLUGGING METHOD (F6) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
  
SIFTING 
 
MIXING 
 
LUBRICATION 
 
COMPRESSION 
 
WEIGHING 
 
Prednisolone, riboflavin -5-sodium 
phosphate, microcrystalline cellulose 
PH112, crospovidone, maize starch, 
colloidal anhydrous silica, lactose 
(DCL 21), magnesium stearate and 
purified talc. 
 
 
 
 
Prednisolone and micro crystalline 
cellulose (PH112) 
Riboflavin -5- sodium phosphate, 
crospovidone, maize starch, and 
lactose (DCL21). 
Colloidal anhydrous sillica. 
Prednisolone, riboflavine -5-sodium 
phosphate, microcrystalline cellulose 
PH112, crospovidone, maize starch, 
colloidal anhydrous silica, lactose 
(DCL 21). 
 
 
 
 
Magnesium stearate and purified talc. 
Collect the tablets and slugging 
  Sifted # 30 mesh 
   Sifted # 40 mesh 
Mixed for 10 min. 
   Sifted # 60 mesh 
    Mixed for 5 min. 
  Passed through 
16#, 20# and 30# 
mesh 
RE-COMPRESSION 
 
The granules were compressed into 
tablets and collected. 
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4.5.3. FORMULATION OF VEHICLE FOR SUSPENDING PREDNISOLONE 
DISPERSIBLE TABLET 
1. Accurately weighed sodium chloride was dissolved in purified water. 
2. Separately sodium carboxy methyl cellulose was dissolved in propylene glycol then 
poured into the sodium chloride mixture. 
3. Methyl hydroxybenzoate and propyl hydroxybenzoate were dissolved in hot purified 
water. Then added into the above mixture. 
4. Finally the volume of solution was made up to 100 ml with purified water. 
 
FLOW CHAT FOR FORMULATION OF VEHICLE SOLUTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sodium chloride + purified water 
Mixed well 
 
 
 
 
Sodium carboxy methyl cellulose       
+ propylene glycol 
 
 
 
 
Methyl hydroxybenzoate and propyl 
hydroxybenzoate was dissolved in   
hot purified water. 
 
 
 
 
Make up to 100 ml with purified 
water. 
Mix well 
 
 
 
 
Filtered and stored in a well closed 
container. 
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Table No. 29: Formulation of Vehicle for Suspending Prednisolone Dispersible Tablet 
 
S. No. Ingredients 
Quantity (mg/100 ml) 
for 1 tablet 
1 Sodium chloride 90 
2 Methyl hydroxybenzoate 230 
3 Propyl hydroxybenzoate 34 
4 Sodium carboxy methyl cellulose 100 
5 Propylene glycol 5000 
6 Purified water To 100 ml 
 
 
4.5.4 EVALUATION OF PREDNISOLONE POWDER/GRANULES 
The powders/granules were evaluated for the following parameters before 
compression into tablets. 
1. Angle of repose  
2. Bulk density   
3. Tapped density  
4. Compressibility index 
5. Hausner’s ratio 
6. Moisture content 
These procedures were discussed earlier in preformulation studies. 
 
4.5.5. EVALUATION OF PREDNISOLONE DISPERSIBLE TABLETS80-88 
The compressed tablets were evaluated for the following parameters. 
 
General appearance 
  The tablets should be free from cracks, depression, pinholes etc. the colour and polish 
of the tablets should be uniform on whole surface. The tablets were examined externally 
under a biconvex lens for surface, cracks, depressions, pinholes, colour, polish, etc. 
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Hardness test or crushing strength 
 Hardness of the tablet is defined as the force required in breaking a tablet in a 
diametric compression test. In this test, a tablet was laced between two anvils, force was 
applied to the anvils and the crushing strength that just causes the tablet to break is recorded. 
Hence hardness is sometimes referred to as “Crushing Strength”. 
            Tablets require certain amount of strength or hardness to withstand mechanical shocks 
of handling in manufacture, packaging and shipping. The hardness of a tablet, like its 
thickness, is a function of the die fill and compression force. At a constant die fill, the 
hardness value increases and thickness decreases as additional compression force is applied. 
At a constant compression force (fixed distance between upper and lower punches), hardness 
increases with increasing die fills and decreases with lower die fills. 
It was measured using Monsanto tablet hardness tester. The values were expressed in 
kg/cm
2
. 
 
Thickness 
Thickness mainly depends up on die filling, physical properties of material to be 
compressed under compression force. The thickness of the tablets was measured by using 
digital vernier callipers. The thickness was denoted in millimetre. 
 
Weight variation test 
20 tablets were individually weighed and the average weight was calculated. Not 
more than two of the individual weights deviate from the average weight by more than the 
percentage deviation shown in Table No. 29. The percentage deviation of the tablets were 
calculated by using the following formula,  
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Table No. 30: Weight variation of tablets and Percentage deviation 
S. No. Average weight of tablet (mg)  Percentage  deviation 
1 130 or less ± 10.0 
2 130-324  ± 7.5 
3 More than 324 ± 5.0 
 
Friability 
The friability of tablets was determined by using Roche friabilator. 20 tablets were 
weighed and placed into the friabilator and rotated at 25 rpm for 4 minutes. Then the tablets 
were taken out, de-dusted and reweighed. The percentage friability of the tablets was 
calculated by the formula. 
 
                         
                         
              
     
 
 
Disintegration time  
The test was carried out on six tablets using 900 ml distilled water at 37
o
C ± 2
o
C was 
used as disintegration media and the time in seconds taken for complete disintegration of the 
tablets with no palpable mass remaining in the apparatus was measured in seconds.  
 
Wetting time 
 A piece of tissue paper (10.75×12 mm) folded twice was placed in a culture dish 
(d=6.5 cm) containing 6 ml of water. A tablet was placed on the paper and the time for 
complete wetting was noted. 
 
Water absorption ratio 
A piece of tissue paper folded twice was placed in a small petri dish containing 6 ml 
of water. A tablet was placed on the tissue paper and allowed to completely wet. The wetted 
tablet was then weighed. The water absorption ratio (R) was calculated by using following 
formula. 
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Where, 
     R    = Water absorption ratio 
     W2 = Weight after wetting 
     W1 = Weight before wetting 
 
In-vitro dispersion time
 
 One tablet was placed into 10 ml of distilled water at 37°±0.5°C. Time required for 
complete dispersion of a tablet was noted. 
 
Uniformity of dispersion 
The fineness of dispersion test was done by two tablets in 100 ml of water and stir 
gently until completely dispersed. A smooth dispersion was obtained which passes through a 
sieve screen with a nominal mesh aperture of 710 mm (sieve no. 22). 
 
Drug content estimation (By UV) 
89,90 
Diluent Preparation 
Methanol:Purified water (30:70). 300 ml methanol added into 700 ml of purified 
water to make 1000 ml of diluent. 
Sample Preparation  
Accurately weighed about 650 mg of crushed tablet power in a clean 100 ml 
volumetric flask and 50 ml of diluents was added. Mixed well and sonicated for 20 minutes. 
Then make up to 100 ml with diluents. Filtered and diluted 1 ml to 100 ml and from this, 5 ml 
was diluted to 10 ml. 
Standard preparation  
Accurately weighed 100 mg of Prednisolone working standard in a clean, 100 ml 
volumetric flask and dissolved into 50 ml of diluents. The volume was making up to 100 ml 
with diluents. 1 ml of this solution was diluted to 100 ml with diluents. From this, 5 ml of the 
resulting solution was diluted to 10 ml with diluents. 
  
CHAPTER 4                                                                                                                               MATERIALS AND METHODS 
 
DEPARTMENT OF PHARMACEUTICS, S.B.C.P, SIVAKASI. Page 73 
 
Procedure 
The absorbance of both the standard and sample preparations was measured at 246 
nm using diluents as a blank. The drug content of prednisolone present per tablet was 
calculated by using the following expression. 
 
 
             
                   
                      
 
                  
   
  
 
   
 
 
  
      
 
   
                 
 
   
 
 
  
 
 
                  
             
      
 
      
            
           
     
 
 
IR spectral analysis 
Compatibility studies were assured by FT-IR studies. The pure drug sample and the 
complete formula of formulation were chosen for the study. The FT-IR spectra’s of the above 
samples were studied after a period of 30 days from preparation of the mixtures, to facilitate 
prompt detection of incompatibility. The spectra’s were obtained by preparing potassium 
bromide (KBr) pellets under dry condition by using pellet press. The spectra of the crude 
drug sample and that of the drug-excipients mixtures were compared to check the 
incompatibility problems, if any.  
 
 
4.5.6.  FORMULATION OF RECTAL SUSPENSION23 
 One Prednisolone dispersible tablet from F6 formulation was placed into a container 
contains 100 ml of vehicle solution. Shaked well for 2-3 minutes for the tablet to disperse. A 
yellow colour suspension was obtained. 
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4.5.7. EVALUATION OF SUSPENSION 
Determination of pH value
91 
The pH value conventionally represents the acidity or alkalinity of an aqueous 
solution. In the I.P. standards and limits of pH have been provided for those 
Pharmacopoeial substances in which pH as a measure of the hydrogen-ion activity is 
important from the standpoint stability or physiological suitability. The pH determination 
is carried out by using pH meter. 
 
Determination of viscosity
91 
 
                The determination of viscosity of newtonian liquids is carried out by means of a 
capillary viscometer, unless otherwise specified. For measurement of viscosity, the 
temperature of the substance being measured must be accurately controlled, since small 
temperature changes may lead to marked changes in viscosity. Viscosity was measured using 
Spindle 61, 50 RPM in Brook field DV- E viscometer. 
 
In-vitro release study
92,93 
The release of Prednisolone from suspension was studied in 900 ml of phosphate 
buffer pH 7.4 as dissolution medium in a U.S.P type II dissolution (paddle) apparatus at 50 
rpm and 37 ± 0.5
o
C temperatures. 10 ml of suspension was placed in a bowl. 5 ml of sample 
was withdrawn at every 10 minutes interval up to one hour; the solution was filtered through 
membrane filter and make up to 10 ml with pH 7.4 phosphate buffer. The sample was 
analyzed in UV double beam spectrophotometer at 246 nm. pH 7.6 phosphate buffer as a 
blank. The percentage drug release was calculated by using following formula. 
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4.5.8. MICROBIOLOGICAL EVALUATION94 
 The formulated suspension was evaluated for microbial limit test. The following tests 
were performed:  
1. Total aerobic microbial count.  
2. Total combined yeast and mould count.  
3. Test for specified microorganisms such as: 
 Escherichia coli 
 Salmonella typhi 
 Staphylococcus aureus 
 Pseudomonas aeruginosa 
 
1. Total aerobic microbial count 
 
Pre-treatment of the sample 
10 ml of the suspension was diluted in buffered sodium chloride-peptone solution pH 
7.0 and the volume made up to 100 ml with the same medium. The pH was adjusted to 7.  
 
For bacteria 
Using petri dishes 9 to 10 cm in diameter, added to each dish a mixture of 1 ml of the 
pre-treated preparation and about 15 ml of a liquefied Casein soya bean digest medium at not 
more than 45ºC. Alternatively, the pre-treated preparation was spreaded on the surface of the 
solidified medium in a petri dish of the same diameter. Two such petri dishes using the same 
dilution was prepared and incubated at 30 to 35°C for 4 days, unless a more reliable count is 
obtained in a shorter time. Formed colonies were counted. 
 
 For total combined yeast and mould 
Proceed as described in the test for bacteria but Sabouraud dextrose agar medium was 
used and the plates were incubated at 20 to 25°C for 5 days. Then, the formed colonies were 
counted. 
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2. Test for specified microorganisms 
Pre-treatment of samples  
Proceed as described below the test for total aerobic microbial count but using lactose 
broth.  
 Escherichia coli:   
The prescribed quantity of suspension was placed in a sterile screw-capped 
container. 50 ml of Casein soya bean digest broth was added. Shaked and allowed to 
stand for 1 hr (4 hrs for gelatin) and homogenised. Loosen the cap and incubated at 36-
38°C for 18 to 24 hrs. Shake the container, 1 ml was transfered to 100 ml of MacConkey 
broth and incubate at 43-45ºC for 18-24 hrs. Subculture was on plates of MacConkey 
broth at 35-37º for 18-72 hrs. Growth of red, non-mucoid colonies of gram-negative rods 
indicates the possible presence of Escherichia coli.  
 
 Salmonella typhi:   
A quantity of the pre-treated preparation was transferred under examination 
containing 1 ml of the product to 100 ml of Nutrient broth in a sterile screw-capped jar. 
Shakes well and allowed to stand for 4 hrs. Loosen the cap and incubated at 35 to 37ºC 
for 24 hrs. 1.0 ml of the enrichment culture was added to 10 ml of Selenite F broth and 
incubated at 36 to 38ºC for 48 hrs. From this culture, subculture on Brilliant green agar 
was prepared. The plates were incubated at 36 to 38ºC for 18 to 24 hrs. Upon 
examination, if none of the colonies formed confirms the sample for the absence for the 
genus Salmonella.  
 
 Pseudomonas aeruginosa:  
100 ml of Casein soya bean digest broth with a quantity of the solution thus 
obtained containing 1 ml of sample suspension was inoculated. After mixing, it was 
incubated at 35 to 37ºC for 24 hrs. The medium for growth, streak a portion of the 
medium on the surface of Cetrimide agar, each plated on petri dishes was examined. 
Covered and incubated at 35 to 37ºC for 18 to 24 hrs.  
 
 Staphylococcus aureus:  
Proceed as described under Pseudomonas aeruginosa. If, upon examination of the 
incubated plates, none of them contains colonies, the sample was absence of 
Staphylococcus aureus. 
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4.5.9. ACCELERATED STABILITY STUDIES95,96 
 Stability studies were aimed at determining the result of aging and storage under 
various conditions on the formulated dispersible tablet. It was carried out to evaluate the 
stability of F6 formulations after storing at different temperatures for a period of 3 months. 
The prepared tablets were kept at three different temperatures 4 + 2°C, 28 + 2°C and 45 + 
2°C for 3 months. Every month the tablets were evaluated for all the physical parameters. 
The in vitro drug release studies were determined by UV double beam spectrophotometer. 
 
Evaluation parameters for stability studies 
1. Colour and appearance 
2. Hardness 
3. Thickness 
4. Weight variation 
5. Friability 
6. Disintegration time 
7. Wetting time 
8. Water absorption ratio 
9. In-vitro dispersion time 
10. Uniformity of dispersion 
11. Drug content estimation 
12. In-vitro drug release 
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5. RESULTS AND DISCUSSION 
 
5.1. PREFORMULATION STUDIES FOR PREDNISOLONE PURE DRUG
 
 
5.1.1. DESCRIPTION 
 
Table No. 31:  Description of Prednisolone 
Properties 
As per I.P. 
Specification 
Observation 
Colour White White 
Physical Nature Crystalline powder Crystalline powder 
Taste Bitter Bitter 
Odour Odourless Odourless 
 
Corollary: 
 Colour, physical nature, taste and odour of Prednisolone were observed and their 
result shows same as the I.P. specification. 
 
5.1.2. SOLUBILITY 
 
Table No. 32: Solubility analysis of Prednisolone 
Active ingredient Aqueous solubility 
Prednisolone Insoluble 
 
Corollary: 
Based on the procedure, the solubility of Prednisolone was found to be insoluble in 
water. 
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5.1.3. PHYSICAL PROPERTIES 
 
Table No. 33: Physical properties of Prednisolone 
Properties I.P. Ranges Observed value 
Melting point 230-235
o
C 233.7
o
C 
Loss on drying Not more than 1.0% 0.78 % 
 
Corollary: 
The observed value for melting point and loss on drying of Prednisolone was found to 
be within the I.P. ranges. 
 
5.1.4. FLOW PROPERTIES 
 
Table No. 34: Flow properties of Prednisolone 
S. No. Properties Observation value Types of flow 
1 Angle of repose 40
o.35΄ Very Poor 
2 Bulk density 0.265 gm/ml - 
3 Tapped density 0.365 gm/ml - 
4 Compressibility Index 27.39 Poor 
5 Hausner’s Ratio 1.37 Very Poor 
 
Corollary: 
 According to the results showed in Table No. 34 the flow property of Prednisolone 
was found to be very poor. So it may require glidants to improve the flow property. 
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5.1.5. PARTICLE SIZE DISTRIBUTION 
 
Table No. 35: Particle size distribution of Prednisolone 
Sieve 
No. 
Empty 
sieve 
weight (gm) 
Quantity 
retained 
(gm) 
Mass 
retained 
(gm) 
Cumulative 
mass 
retained 
Cumulative 
% retained 
Percentage 
passing % 
#20 367.80 368.20 0.40 0.40 4.00 96.00 
#30 417.65 418.16 0.51 0.91 9.10 90.90 
#40 358.05 359.97 1.92 2.83 28.30 71.70 
#60 343.45 349.15 5.70 8.53 85.30 14.70 
#80 340.75 341.72 0.97 9.50 95.00 5.00 
#100 332.50 332.91 0.41 9.91 99.10 0.90 
Base 540.45 540.54 0.09 10.00 100.00 0.00 
 
Corollary: 
 From the particle size distribution analysis, Prednisolone particle size was found to be 
fine powder. 
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5.1.6. DRUG – EXCIPIENTS COMPATIBILITY STUDIES 
Table No. 36: Physical Observation 
S. 
No. 
Composition Initial 
1
st
 
week 
2
nd
 
week 
3
rd
 
week 
1 Prednisolone 
White crystalline 
powder 
NCC NCC NCC 
2 
Prednisolone + Riboflavin-5- sodium 
phosphate 
Sunset yellow 
crystalline powder 
NCC NCC NCC 
3 
Prednisolone + Microcrystalline 
cellulose 
White to off white 
powder 
NCC NCC NCC 
4 Prednisolone + Crospovione 
White to off white 
powder 
NCC NCC NCC 
5 Prednisolone + Maize starch 
White to off white 
powder 
NCC NCC NCC 
6 
Prednisolone + Colloidal anhydrous 
silica 
White to off white 
powder 
NCC NCC NCC 
7 Prednisolone + Lactose (DCL 21) 
White to off white 
powder 
NCC NCC NCC 
8 Prednisolone + Lactose monohydrate 
White to off white 
powder 
NCC NCC NCC 
9 Prednisolone + Methyl hydroxybenzoate 
White to off white 
powder 
NCC NCC NCC 
10 Prednisolone + Propyl hydroxybenzoate 
White to off white 
powder 
NCC NCC NCC 
11 Prednisolone + Magnesium stearate 
White to off white 
powder 
NCC NCC NCC 
12 Prednisolone + Purified talc 
White to off white 
powder 
NCC NCC NCC 
*NCC – No Characteristic change 
Corollary:  
 From the drug excipients compatibility study, it was observed that there were no 
physical changes between drug and excipients. Thus it was concluded that the excipients 
selected for the formulations were compatible with Prednisolone. 
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5.2. EVALUATION OF FORMULATED PREDNISOLONE POWDER/GRANULES 
Table No. 37: Evaluation of Formulated Prednisolone Powders/Granules 
Formulation 
No. 
Angle of 
repose 
(degree) 
Bulk 
density 
(gm/ml) 
Tapped 
density 
(gm/ml) 
Carr’s 
Index 
(%) 
Hausner’s 
ratio 
Moisture 
content                     
(%) 
F1 40
o
.75΄ 0.332 0.436 23.85 1.31 0.89 
F2 41
o
.15΄ 0.391 0.511 23.48 1.30 0.80 
F3 44
o
.26΄ 0.396 0.506 21.70 1.27 0.86 
F4 37
o
.12΄ 0.398 0.512 22.20 1.21 0.85 
F5 36
o
.24΄ 0.411 0.526 21.86 1.22 0.76 
F6 32
o
.27΄ 0.557 0.647 13.91 1.16 0.70 
 
Corollary: 
 The Prednisolone powders/granules were evaluated for different parameters and the 
results are given in Table No. 37. 
 Angle of repose of the powder blend was found to be between 32
o.
27΄ to 44o.26΄. 
Angle of repose for F1 to F3 formulations was within the limit of 41
o
 to 45
o
 and their flow 
properties were passable. F4 and F5 formulations 36
 o
 to 40
 o
 and their flow properties were 
fair. In F6 formulation, the angle of repose is within the limit of 30
o
 to 35
o
.  This indicates the 
granules having good flow property. 
 Bulk density for F1 to F3 formulations was found to be between 0.332 and 0.396 
(gm/ml), F4 and F5 formulations between 0.398 and 0.411 (gm/ml) and F6 formulation 0.557 
(gm/ml). The values were found to be high for Slugging method than direct compression 
method and wet granulation method. This may be due to increase in void space observed in 
granules. 
 Tapped density was found to be between 0.436 and 0.511 (gm/ml) for F1 to F3 
formulations, 0.512 and 0.526 (gm/ml) for F4 and F5 formulations and 0.647 (gm/ml) for F6 
formulations. The values of the direct compression method and wet granulation method were 
found to be decrease when compared to slugging method since the granules size were larger 
than the powder blends. So it does not settle down easily like powders in case of direct 
compression method. 
 Compressibility index was found to be in the range of 21.70 to 23.85 % for F1 to F3 
formulations, 22.20 and 21.86 % for F4 and F5 formulations, 13.91% for F6 formulation. 
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From the observed values the flow type is passable in direct compression and wet granulation 
method and good for slugging method. 
 Hausner’s ratio was found to be between 1.27 to 1.31 for F1 to F3 formulations, 1.28 
and 1.27 for F4 and F5 formulations and 1.16 for F6 formulation. From the observed values 
the flow type is passable for direct compression method and fair for wet granulation method. 
In slugging method, the flow property was good.  
 Moisture content for the F1 to F6 formulations was found to be between 0.7 to 1.0 % 
the moisture content of all formulations were within the limit (1%). 
 
5.3. EVALUATION OF PREDNISOLONE DISPERSIBLE TABLETS 
Description: Yellow coloured round shaped tablets 
 
Table No. 38: Evaluation of Prednisolone Dispersible Tablets 
Parameters F1 F2 F3 F4 F5 F6 
Hardness 
a
 
(kg/cm
2
) 
2.95±0.37 3.40±0.46 2.55±0.69 3.80±0.42 4.35±0.41 2.30±0.42 
Thickness 
a
 
(mm) 
2.93±0.03 2.82±0.04 3.42±0.02 3.01±0.05 3.62±0.06 2.97±0.01 
Weight 
variation 
b
  
(mg) 
131.5±8.40 133 ±9.50 151±12.50 150±1.09 170±1.05 130±0.50 
Friability 
a* 
(%) 
0.23±0.03 0.24±0.05 0.27±0.04 0.26±0.06 0.25±0.07 0.11±0.01 
Disintegration 
time 
c*
 (sec.) 
53.80±2.59 67.00±2.45 72.20±2.86 180.60±1.95 187.40±1.95 51.00±2.07 
Wetting time
*
 
(sec.) 
50.0±1.00 57.6±1.14 55.2±1.48 61.0±1.00 63.0±1.58 46.20±0.84 
Water 
absorption 
ratio
* 
(%) 
54.70±0.25 49.93±0.77 50.77±0.77 51.04±0.06 50.10±0.04 52.99±0.08 
In-vitro 
dispersion 
time
*
 (min.) 
2.06±0.03 2.15±0.19 2.33±0.43 2.49±0.37 2.55±0.06 1.32±0.01 
Uniformity of 
dispersion 
Pass 
Pass Pass Pass Pass Pass 
Drug content 
d
 (%) 
98.50 99.20 99.43 99.86 99.95 99.99 
Note: a = 10; b = 20; c = 6; d = 15 
* Values are expressed as mean ± SD, n = 5 
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Corollary: 
 F1 formulation having high weight variation due to the poor flow property of powder. 
So the quantity of glidant was increased in the F2 formulation. Then also the weight variation 
was high due to the poor flow property of powder. 
 So the weight of the tablet was increased up to 150 mg by increasing the excipients in 
F3 formulation. This formulation also having high weight variation because the flow of 
powder was poor. 
 In F4 formulation, wet granulation method was chosen to avoid the weight variation. 
In this method the flow property was found to be fair and the weight variation was within the 
limits. But the disintegration time and in-vitro dispersion time was found to be high. 
 That’s why the quantity of excipients was increased from 150 mg to 170 mg in F5 
formulation. Here also the same problem occur, disintegration time and in-vitro dispersion 
time was somewhat more. 
 Then slugging method was preferred for F6 formulation. The average weight of one 
tablet was reduced to 130 mg. The granules obtained are of uniform in size. The flow 
property of the granules was found to be good. Disintegration time and in vitro dispersion 
time was reduced when compared to F5 formulation.  
 With the above data’s F6 formulation was selected as a best formulation. Because its 
passes the all parameters. So this F6 formulation may suitable as a dispersible tablet 
formulation for rectal suspension formulation. 
 
5.4. IR SPECTRAL ANALYSIS 
 The FTIR studies of pure Prednisolone and F6 formulation were carried out to study 
the interaction between the drug and excipients. The results are shown in Table No. 39 & 40 
and Figure: 8 & 9. 
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Figure 8: FT-IR Spectrum of Pure Prednisolone 
 
Table No. 39: IR Spectrum of Prednisolone  
S. No. Wave number (cm
-1
) Signal assignment 
1 3355 OH stretching 
2 2929 Alkane C-H stretching 
3 1711 Acyclic stretching 
4 1653 Aliphatic C-H stretching 
5 1629 C=C stretching 
6 1372 Alkane C-H bending 
7 1061 C-O stretching 
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Figure 9: FT- IR Spectrum of F6 formulation 
 
 
Table No. 40: IR Spectrum of F6 formulation 
S. No. Wave number (cm
-1
) Signal assignment 
1 3370 OH stretching 
2 2915 Alkane C-H stretching 
3 1710 Acyclic stretching 
4 1654 Aliphatic C-H stretching 
5 1623 C=C stretching 
6 1383 Alkane C-H bending 
7 1070 C-O stretching 
 
Corollry: 
 From the IR spectral analysis, the result reveals that there was no interaction between 
the drug and excipients 
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5.5. EVALUATION STUDIES FOR RECTAL SUSPENSION 
 
Table No. 41: Evaluation of F6 formulation in Rectal Suspension 
S. No. Parameter F6 
1 pH 6.2 
2 Viscosity (cps) 55.9 
Corollary: 
 From the above data the pH of F6 formulation was found to be 6.2 and the viscosity 
of F6 formulation was 55.9. High viscosity leads to high retention time.  
 
IN-VITRO DRUG RELEASE STUDY 
 
Table No. 42: In-vitro drug release of Prednisolone from F6 Formulation in Rectal 
Suspension* 
 
S. No. Time in minutes % drug released 
1 10 9.62 ± 0.09 
2 20 21.54 ± 0.06 
3 30 53.85 ± 0.03 
4 40 78.17 ± 0.02 
5 50 89.96 ± 0.02 
6 60 99.07 ± 0.02 
 
Note: * Values are expressed as mean ± SD, n = 5 
 
 
 
 
 
 
CHAPTER 5                                                                                                                                 RESULTS AND DISCUSSION 
 
DEPARTMENT OF PHARMACEUTICS, S.B.C.P, SIVAKASI. Page 88 
 
 
 
 
Figure 10: Graph for in-vitro drug release of F6 formulation in Rectal Suspension 
 
Corollary: 
 The in vitro drug release of Prednisolone from F6 formulation in rectal suspension 
was found to be 99.07 ± 0.02 % at 60 min. 
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5.6. MICROBIOLOGICAL EVALUATION 
 The formulated suspension was evaluated microbiologically to determine the presence 
or absence of aerobic microbes, combined yeast and mould, Escherichia Coli, Salmonella 
typhi, Staphylococcus aureus and Pseudomonas aeruginosa. The results were given in Table 
No. 43. 
 
Table No. 43: Microbial Limit test for F6 formulation in Rectal Suspension 
S. No. Test/ specified microorganisms Limits Report 
1 Total aerobic viable count NMT 1000 cfu/ml 30 cfu/ml 
2 Total combined yeast and mould count NMT 100 cfu/ml 10 cfu/ml 
3 Escherichia coli Absent/ml Absent 
4 Salmonella Absent/ml Absent 
5 Pseudomonas aeruginosa Absent/ml Absent 
6 Staphylococcus aureus Absent/ml Absent 
*cfu – Colony Forming Units 
 
Corollary: 
 From the above data, the total aerobic viable count and total combined yeast count 
were observed that the cfu limits of formulated rectal suspension formulations were found to 
be within the limits. All the specified microorganisms were found to be absent. Thus the 
rectal suspension formulation was microbiologically stable. 
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5.7. ACCELERATED STABILITY STUDIES 
Table No. 44: Stability studies for F6 formulation 
Parameters Initial period 
4
°
 ± 2
°
 C 28
°
 ± 2
° 
C 45
°
 ± 2
°
 C 
1
st
 month 2
nd
 month 3
rd
 month 1
st
 month 2
nd
 month 3
rd
 month 1
st
 month 2
nd
 month 3
rd
 month 
Colour  Yellow Yellow Yellow Yellow Yellow Yellow Yellow Yellow Yellow Yellow 
Hardness
a
 
(kg/cm
2
) 
2.30±0.42 2.30±0.29 2.31±0.09 2.30±0.38 2.30 ± 0.31 2.32 ± 0.01 2.30 ± 0.45  2.31 ± 0.09 2.32 ± 0.09 2.30 ± 0.09 
Thickness
a
(mm) 2.97 ± 0.01 2.97 ± 0.04 2.96 ± 0.05 2.97 ± 0.10 2.97 ± 0.03 2.96 ± 0.28 2.96 ± 0.36 2.97 ± 0.05 2.96 ± 0.08 2.97 ± 0.02 
Weight 
variation
b
  (mg) 
130.00 ± 0.50 129.00 ± 0.40 130.00 ± 0.10 131.00 ± 0.05 130.00 ± 0.60 130.00 ± 0.18 130.00 ± 0.10 129.00 ± 0.50 130.00 ± 0.20 131.00 ± 0.10 
Friability
a* 
(%) 0.11 ± 0.01 0.10 ± 0.01 0.11 ± 0.11 0.11 ± 0.15 0.11 ± 0.01 0.10 ± 0.01 0.11 ± 0.04 0.12 ± 0.01 0.10 ± 0.01 0.11 ± 0.05 
Disintegration 
time
c*
 (sec) 
51.00 ± 2.07 50.30 ± 1.20 49.80 ± 1.44 49.90 ± 1.12 50.10 ± 1.30  49.90 ±2.04 50.10 ±1.00  50.10 ±1.20 49.40 ± 3.44 49.90 ± 1.20 
Wetting time
*
 
(sec.) 
46.20 ± 0.84 46.30 ± 0.04 45.90 ± 0.13 46.10 ± 0.01 46.50 ± 0.04 44.80 ± 0.54 46.10 ± 0.61 46.50 ±0.14 45.80 ± 0.04 47.10 ± 0.01 
Water 
absorption 
ratio
*
 (%) 
52.99 ± 0.08 51.99 ± 0.17 52.02 ± 0.05 52.05 ± 0.10 51.79 ± 0.07 51.54 ± 0.65 52.19 ± 0.10 51.99 ±0.07 52.54 ± 0.05 52.49 ± 0.10 
In-vitro 
dispersion time
*
 
(min.) 
1.32 ± 0.01 1.31 ± 0.05 1.31 ± 0.03 1.31 ± 0.18 1.32 ± 0.10 1.32 ± 0.08 1.31 ± 0.23 1.32 ± 0.05 1.32 ± 0.03 1.31 ± 0.28 
Uniformity of 
dispersion* 
Pass Pass Pass Pass Pass Pass Pass Pass Pass Pass 
Drug content
d
 
(%) 
99.99 99.98 99.98 99.98  99.99 99.98  99.98  99.98  99.97 99.96  
 
Note: a = 10; b = 20; c = 6; d = 15 
* Values are expressed as mean ± SD, n = 5 
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Corollary: 
 According to the procedure the stability study of Prednisolone dispersible tablet was carried out at storage condition for 4
0
 ± 2
0
 C,         
28
0
 ± 2
0 
C and 45
0
 ± 2
0
 C with a period of three months. The results revels that there was no change all physical parameters. 
 
IN-VITRO DRUG RELEASE STUDY 
Table No. 45: Stability study for in-vitro drug release of Prednisolone from F6 formulation in Rectal Suspension 
S. No. 
Time in 
minutes 
Initial 
period 
4
°
 ± 2
°
 C 28
°
 ± 2
° 
C 45
°
 ± 2
°
 C 
1
st
 month 2
nd
 month 3
rd
 month 1
st
 month 2
nd
 month 3
rd
 month 1
st
 month 2
nd
 month 3
rd
 month 
1 10 9.63 9.62 9.61 9.59 9.64 9.62 9.60 9.65 9.60 9.58 
2 20 21.56 21.25 21.49 21.58 22.15 21.78 21.54 22.05 21.69 21.48 
3 30 53.87 54.05 53.78 53.84 54.06 54.25 53.94 54.15 53.95 53.74 
4 40 78.19 78.44 78.38 78.15 78.74 78.54 78.32 78.94 78.68 78.25 
5 50 89.95 88.81 89.23 89.99 88.78 89.73 89.92 88.9 89.65 89.78 
6 60 99.06  99.06  99.06  99.05  99.06  99.05  99.05  99.05  99.05  99.04  
 
Corollary: 
 The drug release of Prednisolone from the rectal suspension has no changes for a period of three months even storing at three different 
temperatures. 
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6. SUMMARY AND CONCLUSION 
 
SUMMARY 
 
This work demonstrate that the formulation and evaluation of Prednisolone retention 
enema as the dispersible tablet with vehicle for the effective treatment of UC. It was carried 
out by performing the preformulation studies, formulation of Prednisolone dispersible tablet, 
formulation of vehicle, evaluation parameters, microbiology studies, in-vitro release studies 
and stability studies. 
 For pure Prednisolone, preformulation studies such as angle of repose, bulk density, 
tapped density, compressibility index, Hausner’s ratio, moisture content and particle 
size analysis were performed. The preformulation results revealed that the 
Prednisolone having poor flow properties, so it may requires glidants. The moisture 
content showed within 1% and the particle size was found to be fine powder. 
 
 Drug – excipients incompatibility study was performed by physical observation. That 
there were no physical changes between drug and excipients. Thus it was concluded 
that the excipients selected for the formulation were compatible with Prednisolone. 
 
 Prednisolone dispersible tablets were formulated by direct compression method, wet 
granulation method and slugging method using crospovidone as superdisintegrant.  
 
 The formulated powder/granule blend was evaluated for precompression parameters 
like angle of repose, bulk density, tapped density, Hausner’s ratio, compressibility 
index and moisture content. The results obtained indicate that F6 formulation 
formulated by slugging method has good flow property. The moisture content was 
within 1%. 
 
 The formulated tablets were evaluated for hardness, thickness, weight variation, 
friability, disintegration time, wetting time, water absorption ratio, in-vitro dispersion 
time, uniformity of dispersion and drug content. All these parameters were found to 
be within the limits for F6 formulation. 
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 IR spectroscopic analysis was carried out to determine the compatibility of drug and 
excipients. The IR spectrum showed that the drug was compatible with excipients, 
which was used in the F6 formulation. 
 
 From the data’s obtained from precompression parameters and tablet evaluation F6 
formulation was selected for further studies.  
 
 The rectal suspension was prepared by using F6 formulation. 
 
 pH and viscosity of the rectal suspension were carried out and the pH was found to be 
6.2 and the viscosity was found to be 55.9 cps. 
 
 In-vitro drug release of Prednisolone from F6 formulation in rectal suspension was 
99.07 ± 0.02 % at 60 minutes. 
 
 The microbiology studies for the rectal suspension with F6 formulation were carried 
out to determine the presence/absence of microorganisms in the formulation. The 
results showed that there was absence of microorganisms in F6 formulation in rectal 
suspension. So the formulation was microbiologically stable. 
 
 The accelerated stability studies were performed for F6 formulation at three different 
temperatures such as 4
0
 ± 2
0
 C, 28
0
 ± 2
0 
C and 45
0
 ± 2
0
 C for a period of three months. 
In this storage condition for the three months period, there were no changes in all the 
tablets physical parameters. 
 
 The accelerated stability studies of F6 formulation in rectal suspension (in vitro drug 
release) was also performed by stored in three different storage conditions for the 
period of three months. The results showed that there were no changes in percentage 
drug release.  
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CONCLUSION 
 
Formulation and evaluation of Prednisolone retention enema as dispersible tablet with 
vehicle for the effective treatment of UC was successfully carried out. 
Preformulation studies of powder/granules, formulation of Prednisolone dispersible 
tablets, formulation of vehicle, tablets evaluation parameters, in-vitro release study, 
microbiological evaluation and accelerated stability studies (three different temperatures) 
were performed. From all the above observations it was concluded that the formulation F6 by 
slugging method was better one compared to the other formulations.  
Thus it can be concluded that the Prednisolone retention enema as dispersible tablet 
with vehicle possesses promising future delivery of rectal formulation of drugs in suspension 
form for the effective treatment of UC. 
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7. FUTURE STUDY 
 
Formulation F6 may be further investigated for following studies 
 In-vivo study for drug release. 
 Scale up techniques of the F6 formulation. 
 The treatment of UC affected patients with the developed formulation. 
 Stability study test for prolonged time period. 
 Based on the reproducible results produced from batch to batch the company will 
decide to launch the product in future. 
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